Implantable medical device with rechargeable battery

Information

  • Patent Grant
  • 11116988
  • Patent Number
    11,116,988
  • Date Filed
    Friday, March 31, 2017
    7 years ago
  • Date Issued
    Tuesday, September 14, 2021
    2 years ago
Abstract
Implantable medical devices such as leadless cardiac pacemakers may include a rechargeable power source. In some cases, a system may include an implanted device including a receiving antenna and an external transmitter that transmits radiofrequency energy that may be captured by the receiving antenna and then be converted into electrical energy that may be used to recharge a rechargeable power source. Accordingly, since the rechargeable power source does not have to maintain sufficient energy stores for the expected life of the implanted device, the power source itself and thus the implanted device, may be made smaller while still meeting device longevity expectations.
Description
TECHNICAL FIELD

The disclosure relates generally to implantable medical devices, and more particularly to implantable medical devices that have a power source that may be wirelessly recharged from a remote location.


BACKGROUND

Cardiac pacemakers such as leadless cardiac pacemakers are used to sense and pace hearts that are susceptible to a variety of incorrect heart rhythms, including but not limited to bradycardia, which is a slow heart rate, and tachycardia, which is a high heart rate. In many leadless cardiac pacemakers, due to their relatively small size, a relatively large fraction of the internal space of the leadless cardiac pacemaker is consumed by a battery. As the battery life determines the potential useful life expectancy of the leadless cardiac pacemaker, there is a desire to make the batteries as large as possible within the confines of the available space.


What would be desirable is an implantable medical device that has a long useful life expectancy while not requiring as much battery space, thereby permitting a significantly smaller device size. A smaller device size may make the device more easily deliverable and implantable in the body, allow the device to be implantable in smaller and more confined spaces in the body, and/or may make the device less expensive to produce.


SUMMARY

The disclosure is directed to implantable medical that provide a long lasting power source within a smaller device housing. While a leadless cardiac pacemaker is used as an example implantable medical device, the disclosure may be applied to any suitable implantable medical device including, for example, neuro-stimulators, diagnostic devices including those that do not deliver therapy, and/or any other suitable implantable medical device as desired.


In some cases, the disclosure pertains to implantable medical devices such as leadless cardiac pacemakers that include a rechargeable power source such as a rechargeable battery, a rechargeable capacitor or a rechargeable supercapacitor. In some cases, a system may include an implanted device including a receiving antenna and an external transmitter that transmits radiofrequency energy that may be captured by the receiving antenna and then converted into electrical energy that may be used to recharge the rechargeable power source. Accordingly, since the rechargeable power source does not have to maintain sufficient energy stores in a single charge for the entire expected life of the implanted device, the power source itself and thus the implanted device, may be made smaller while still meeting device longevity expectations.


In an example of the disclosure, an implantable medical device (IMD) that is configured to be implanted within a patient includes a housing configured for trans-catheter deployment and a plurality of electrodes that are exposed external to the housing. Therapeutic circuitry is disposed within the housing and may be operatively coupled to the plurality of electrodes and configured to sense one or more signals via one or more of the plurality of electrodes and/or to stimulate tissue via one or more of the plurality of electrodes. A rechargeable power source may be disposed within the housing and may be configured to power the therapeutic circuitry. A receiving antenna may be disposed relative to the housing and may be configured to receive transmitted radiative Electro-Magnetic (EM) energy through the patient's body. Charging circuitry may be operably coupled with the receiving antenna and the rechargeable power source and may be configured to use the radiative EM energy received via the receiving antenna to charge the rechargeable power source.


Alternatively or additionally to any of the embodiments above, the IMD may also include a secondary battery disposed within the housing and operatively coupled to the therapeutic circuitry, the secondary battery functioning as a backup battery to the rechargeable power source.


Alternatively or additionally to any of the embodiments above, the secondary battery is a non-rechargeable battery.


Alternatively or additionally to any of the embodiments above, the IMD is a leadless cardiac pacemaker (LCP).


Alternatively or additionally to any of the embodiments above, the housing is substantially transparent to radiative EM energy.


Alternatively or additionally to any of the embodiments above, the housing may include a ceramic housing, a glass housing, or a polymeric housing.


Alternatively or additionally to any of the embodiments above, the receiving antenna may include a first metal pattern formed on an outer surface of a sleeve insert and a second metal pattern formed on an inner surface of the sleeve insert, and the sleeve insert is configured to be inserted into an elongated cavity of the housing of the IMD.


Alternatively or additionally to any of the embodiments above, the receiving antenna may include a first metal pattern formed on an outer surface of an outer sleeve and a second metal pattern formed on an inner surface of the outer sleeve, and the outer sleeve is configured to fit over and be secured relative to the housing of the IMD.


Alternatively or additionally to any of the embodiments above, at least one of the plurality of electrodes forms part of the receiving antenna.


In another example of the disclosure, an implantable medical device (IMD) configured to be implanted within a patient includes a housing that is substantially transparent to radiative Electro-Magnetic (EM) energy along at least part of its length and circuitry that is disposed within the housing. A plurality of electrodes may be exposed external to the housing and operatively coupled to the circuitry. A rechargeable power source may be disposed within the housing and may be configured to power the IMD including the circuitry. A receiving antenna may be disposed within the housing and may be configured to receive transmitted radiative EM energy through the at least part of the housing that is substantially transparent to radiative EM energy. The circuit may be operably coupled with the receiving antenna and the rechargeable power source and be configured to use the radiative EM energy received via the receiving antenna to charge the rechargeable power source.


Alternatively or additionally to any of the embodiments above, the IMD is a leadless cardiac pacemaker (LCP).


Alternatively or additionally to any of the embodiments above, the IMD is an implantable monitoring device.


Alternatively or additionally to any of the embodiments above, the IMD is an implantable sensor.


Alternatively or additionally to any of the embodiments above, the receiving antenna may include a first receiving antenna having a first null and a second receiving antenna having a second null offset from the first null.


Alternatively or additionally to any of the embodiments above, the housing may include ceramic.


Alternatively or additionally to any of the embodiments above, the housing may include glass.


Alternatively or additionally to any of the embodiments above, the receiving antenna may be configured to receive sufficient radiative EM energy from a wavelength band of radiative EM energy transmitted from outside the patient to recharge the rechargeable power source at a rate faster than the rechargeable power source is depleted by powering the IMD when the wavelength band of radiative EM energy is transmitted at an intensity that does not cause heat damage to the patient.


Alternatively or additionally to any of the embodiments above, at least a portion of the housing has a substantially cylindrical profile and the receiving antenna includes a planar antenna that has been conformed to the substantially cylindrical profile.


In another example of the disclosure, an implantable medical device (IMD) configured to be implanted within a patient includes a housing forming at least part of a receiving antenna, wherein the receiving antenna is configured to receive transmitted radiative Electro-Magnetic (EM) energy through the patient's body. A plurality of electrodes may be exposed external to the housing and circuitry may be disposed within the housing. The circuitry may be operatively coupled to the plurality of electrodes and may be configured to sense one or more signals via one or more of the plurality of electrodes and/or may stimulate tissue via one or more of the plurality of electrodes. A rechargeable power source may be disposed within the housing and may be configured to power the circuitry. Charging circuitry may be operably coupled with the receiving antenna and the rechargeable power source and may be configured to use the radiative EM energy received via the receiving antenna to charge the rechargeable power source.


Alternatively or additionally to any of the embodiments above, the housing may form one or more layers of the receiving antenna.


The above summary of some illustrative embodiments is not intended to describe each disclosed embodiment or every implementation of the present disclosure. The Figures and Description which follow more particularly exemplify these and other illustrative embodiments.





BRIEF DESCRIPTION OF THE FIGURES

The disclosure may be more completely understood in consideration of the following description in connection with the accompanying drawings, in which:



FIG. 1 is a schematic block diagram of an illustrative leadless cardiac pacemaker (LCP);



FIG. 2 is a schematic block diagram of an illustrative medical device that may be used in conjunction with the LCP of FIG. 1;



FIG. 3 is a schematic diagram of a patient including a rechargeable implantable medical device system;



FIG. 4 is a schematic diagram of an illustrative implantable medical device (IMD) according to an example of the disclosure;



FIG. 5 is a schematic diagram of another illustrative IMD according to an example of the disclosure;



FIG. 6 is a schematic diagram of another IMD according to an example of the disclosure;



FIG. 7 is a partial cross-sectional side view of an LCP according to an example of the disclosure;



FIG. 8 is a schematic diagram of an illustrative IMD with an inner sleeve insert;



FIG. 9 is a schematic diagram of an illustrative IMD with an outer sleeve; and



FIGS. 10-14 are schematic diagrams showing example receiving antenna configurations.





While the disclosure is amenable to various modifications and alternative forms, specifics thereof have been shown by way of example in the drawings and will be described in detail. It should be understood, however, that the intention is not to limit the disclosure to the particular embodiments described. On the contrary, the intention is to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the disclosure.


DESCRIPTION

For the following defined terms, these definitions shall be applied, unless a different definition is given in the claims or elsewhere in this specification.


All numeric values are herein assumed to be modified by the term “about,” whether or not explicitly indicated. The term “about” generally refers to a range of numbers that one of skill in the art would consider equivalent to the recited value (i.e., having the same function or result). In many instances, the terms “about” may include numbers that are rounded to the nearest significant figure.


The recitation of numerical ranges by endpoints includes all numbers within that range (e.g. 1 to 5 includes 1, 1.5, 2, 2.75, 3, 3.80, 4, and 5).


As used in this specification and the appended claims, the singular forms “a”, “an”, and “the” include plural referents unless the content clearly dictates otherwise. As used in this specification and the appended claims, the term “or” is generally employed in its sense including “and/or” unless the content clearly dictates otherwise.


It is noted that references in the specification to “an embodiment”, “some embodiments”, “other embodiments”, etc., indicate that the embodiment described may include one or more particular features, structures, and/or characteristics. However, such recitations do not necessarily mean that all embodiments include the particular features, structures, and/or characteristics. Additionally, when particular features, structures, and/or characteristics are described in connection with one embodiment, it should be understood that such features, structures, and/or characteristics may also be used connection with other embodiments whether or not explicitly described unless clearly stated to the contrary.


The following description should be read with reference to the drawings in which similar structures in different drawings are numbered the same. The drawings, which are not necessarily to scale, depict illustrative embodiments and are not intended to limit the scope of the disclosure.



FIG. 1 is a conceptual schematic block diagram of an illustrative leadless cardiac pacemaker (LCP) that may be implanted on the heart or within a chamber of the heart and may operate to sense physiological signals and parameters and deliver one or more types of electrical stimulation therapy to the heart of the patient. Example electrical stimulation therapy may include bradycardia pacing, rate responsive pacing therapy, cardiac resynchronization therapy (CRT), anti-tachycardia pacing (ATP) therapy and/or the like. As can be seen in FIG. 1, the LCP 100 may be a compact device with all components housed within the LCP 100 or directly on a housing 120. In some instances, the LCP 100 may include one or more of a communication module 102, a pulse generator module 104, an electrical sensing module 106, a mechanical sensing module 108, a processing module 110, an energy storage module 112, and electrodes 114.


As depicted in FIG. 1, the LCP 100 may include electrodes 114, which can be secured relative to the housing 120 and electrically exposed to tissue and/or blood surrounding the LCP 100. The electrodes 114 may generally conduct electrical signals to and from the LCP 100 and the surrounding tissue and/or blood. Such electrical signals can include communication signals, electrical stimulation pulses, and intrinsic cardiac electrical signals, to name a few. Intrinsic cardiac electrical signals may include electrical signals generated by the heart and may be represented by an electrocardiogram (ECG).


The electrodes 114 may include one or more biocompatible conductive materials such as various metals or alloys that are known to be safe for implantation within a human body. In some instances, the electrodes 114 may be generally disposed on either end of the LCP 100 and may be in electrical communication with one or more of modules the 102, 104, 106, 108, and 110. In embodiments where the electrodes 114 are secured directly to the housing 120, an insulative material may electrically isolate the electrodes 114 from adjacent electrodes, the housing 120, and/or other parts of the LCP 100. In some instances, some or all of the electrodes 114 may be spaced from the housing 120 and may be connected to the housing 120 and/or other components of the LCP 100 through connecting wires. In such instances, the electrodes 114 may be placed on a tail (not shown) that extends out away from the housing 120. As shown in FIG. 1, in some embodiments, the LCP 100 may include electrodes 114′. The electrodes 114′ may be in addition to the electrodes 114, or may replace one or more of the electrodes 114. The electrodes 114′ may be similar to the electrodes 114 except that the electrodes 114′ are disposed on the sides of the LCP 100. In some cases, the electrodes 114′ may increase the number of electrodes by which the LCP 100 may deliver communication signals and/or electrical stimulation pulses, and/or may sense intrinsic cardiac electrical signals, communication signals, and/or electrical stimulation pulses.


The electrodes 114 and/or 114′ may assume any of a variety of sizes and/or shapes, and may be spaced at any of a variety of spacings. For example, the electrodes 114 may have an outer diameter of two to twenty millimeters (mm). In other embodiments, the electrodes 114 and/or 114′ may have a diameter of two, three, five, seven millimeters (mm), or any other suitable diameter, dimension and/or shape. Example lengths for the electrodes 114 and/or 114′ may include, for example, one, three, five, ten millimeters (mm), or any other suitable length. As used herein, the length is a dimension of the electrodes 114 and/or 114′ that extends away from the outer surface of the housing 120. In some instances, at least some of the electrodes 114 and/or 114′ may be spaced from one another by a distance of twenty, thirty, forty, fifty millimeters (mm), or any other suitable spacing. The electrodes 114 and/or 114′ of a single device may have different sizes with respect to each other, and the spacing and/or lengths of the electrodes on the device may or may not be uniform.


In the embodiment shown, the communication module 102 may be electrically coupled to the electrodes 114 and/or 114′ and may be configured to deliver communication pulses to tissues of the patient for communicating with other devices such as sensors, programmers, other medical devices, and/or the like. Communication signals, as used herein, may be any modulated signal that conveys information to another device, either by itself or in conjunction with one or more other modulated signals. In some embodiments, communication signals may be limited to sub-threshold signals that do not result in capture of the heart yet still convey information. The communication signals may be delivered to another device that is located either external or internal to the patient's body. In some instances, the communication may take the form of distinct communication pulses separated by various amounts of time. In some of these cases, the timing between successive pulses may convey information. The communication module 102 may additionally be configured to sense for communication signals delivered by other devices, which may be located external or internal to the patient's body.


The communication module 102 may communicate to help accomplish one or more desired functions. Some example functions include delivering sensed data, using communicated data for determining occurrences of events such as arrhythmias, coordinating delivery of electrical stimulation therapy, and/or other functions. In some cases, the LCP 100 may use communication signals to communicate raw information, processed information, messages and/or commands, and/or other data. Raw information may include information such as sensed electrical signals (e.g. a sensed ECG), signals gathered from coupled sensors, and the like. In some embodiments, the processed information may include signals that have been filtered using one or more signal processing techniques. Processed information may also include parameters and/or events that are determined by the LCP 100 and/or another device, such as a determined heart rate, timing of determined heartbeats, timing of other determined events, determinations of threshold crossings, expirations of monitored time periods, accelerometer signals, activity level parameters, blood-oxygen parameters, blood pressure parameters, heart sound parameters, and the like. In some cases, processed information may, for example, be provided by a chemical sensor or an optically interfaced sensor. Messages and/or commands may include instructions or the like directing another device to take action, notifications of imminent actions of the sending device, requests for reading from the receiving device, requests for writing data to the receiving device, information messages, and/or other messages commands.


In at least some embodiments, the communication module 102 (or the LCP 100) may further include switching circuitry to selectively connect one or more of the electrodes 114 and/or 114′ to the communication module 102 in order to select which of the electrodes 114 and/or 114′ that the communication module 102 delivers communication pulses with. It is contemplated that the communication module 102 may be communicating with other devices via conducted signals, radio frequency (RF) signals, optical signals, acoustic signals, inductive coupling, and/or any other suitable communication methodology. Where the communication module 102 generates electrical communication signals, the communication module 102 may include one or more capacitor elements and/or other charge storage devices to aid in generating and delivering communication signals. In the embodiment shown, the communication module 102 may use energy stored in the energy storage module 112 to generate the communication signals. In at least some examples, the communication module 102 may include a switching circuit that is connected to the energy storage module 112 and, with the switching circuitry, may connect the energy storage module 112 to one or more of the electrodes 114/114′ to generate the communication signals.


As shown in FIG. 1, a pulse generator module 104 may be electrically connected to one or more of the electrodes 114 and/or 114′. The pulse generator module 104 may be configured to generate electrical stimulation pulses and deliver the electrical stimulation pulses to tissues of a patient via one or more of the electrodes 114 and/or 114′ in order to effectuate one or more electrical stimulation therapies. Electrical stimulation pulses as used herein are meant to encompass any electrical signals that may be delivered to tissue of a patient for purposes of treatment of any type of disease or abnormality. For example, when used to treat heart disease, the pulse generator module 104 may generate electrical stimulation pacing pulses for capturing the heart of the patient, i.e. causing the heart to contract in response to the delivered electrical stimulation pulse. In some of these cases, the LCP 100 may vary the rate at which the pulse generator module 104 generates the electrical stimulation pulses, for example in rate adaptive pacing. In other embodiments, the electrical stimulation pulses may include defibrillation/cardioversion pulses for shocking the heart out of fibrillation or into a normal heart rhythm. In yet other embodiments, the electrical stimulation pulses may include anti-tachycardia pacing (ATP) pulses. It should be understood that these are just some examples. When used to treat other ailments, the pulse generator module 104 may generate electrical stimulation pulses suitable for neurostimulation therapy or the like. The pulse generator module 104 may include one or more capacitor elements and/or other charge storage devices to aid in generating and delivering appropriate electrical stimulation pulses. In at least some embodiments, the pulse generator module 104 may use energy stored in the energy storage module 112 to generate the electrical stimulation pulses. In some particular embodiments, the pulse generator module 104 may include a switching circuit that is connected to the energy storage module 112 and may connect the energy storage module 112 to one or more of the electrodes 114/114′ to generate electrical stimulation pulses.


The LCP 100 may further include an electrical sensing module 106 and a mechanical sensing module 108. The electrical sensing module 106 may be configured to sense intrinsic cardiac electrical signals conducted from the electrodes 114 and/or 114′ to the electrical sensing module 106. For example, the electrical sensing module 106 may be electrically connected to one or more of the electrodes 114 and/or 114′ and the electrical sensing module 106 may be configured to receive cardiac electrical signals conducted through the electrodes 114 and/or 114′ via a sensor amplifier or the like. In some embodiments, the cardiac electrical signals may represent local information from the chamber in which the LCP 100 is implanted. For instance, if the LCP 100 is implanted within a ventricle of the heart, cardiac electrical signals sensed by the LCP 100 through the electrodes 114 and/or 114′ may represent ventricular cardiac electrical signals. The mechanical sensing module 108 may include, or be electrically connected to, various sensors, such as accelerometers, including multi-axis accelerometers such as two- or three-axis accelerometers, gyroscopes, including multi-axis gyroscopes such as two- or three-axis gyroscopes, blood pressure sensors, heart sound sensors, piezoelectric sensors, blood-oxygen sensors, and/or other sensors which measure one or more physiological parameters of the heart and/or patient. Mechanical sensing module 108, when present, may gather signals from the sensors indicative of the various physiological parameters. The electrical sensing module 106 and the mechanical sensing module 108 may both be connected to the processing module 110 and may provide signals representative of the sensed cardiac electrical signals and/or physiological signals to the processing module 110. Although described with respect to FIG. 1 as separate sensing modules, in some embodiments, the electrical sensing module 106 and the mechanical sensing module 108 may be combined into a single module. In at least some examples, the LCP 100 may only include one of the electrical sensing module 106 and the mechanical sensing module 108. In some cases, any combination of the processing module 110, the electrical sensing module 106, the mechanical sensing module 108, the communication module 102, the pulse generator module 104 and/or the energy storage module may be considered a controller of the LCP 100.


The processing module 110 may be configured to direct the operation of the LCP 100 and may, in some embodiments, be termed a controller. For example, the processing module 110 may be configured to receive cardiac electrical signals from the electrical sensing module 106 and/or physiological signals from the mechanical sensing module 108. Based on the received signals, the processing module 110 may determine, for example, occurrences and types of arrhythmias and other determinations such as whether the LCP 100 has become dislodged. The processing module 110 may further receive information from the communication module 102. In some embodiments, the processing module 110 may additionally use such received information to determine occurrences and types of arrhythmias and/or and other determinations such as whether the LCP 100 has become dislodged. In still some additional embodiments, the LCP 100 may use the received information instead of the signals received from the electrical sensing module 106 and/or the mechanical sensing module 108—for instance if the received information is deemed to be more accurate than the signals received from the electrical sensing module 106 and/or the mechanical sensing module 108 or if the electrical sensing module 106 and/or the mechanical sensing module 108 have been disabled or omitted from the LCP 100.


After determining an occurrence of an arrhythmia, the processing module 110 may control the pulse generator module 104 to generate electrical stimulation pulses in accordance with one or more electrical stimulation therapies to treat the determined arrhythmia. For example, the processing module 110 may control the pulse generator module 104 to generate pacing pulses with varying parameters and in different sequences to effectuate one or more electrical stimulation therapies. As one example, in controlling the pulse generator module 104 to deliver bradycardia pacing therapy, the processing module 110 may control the pulse generator module 104 to deliver pacing pulses designed to capture the heart of the patient at a regular interval to help prevent the heart of a patient from falling below a predetermined threshold. In some cases, the rate of pacing may be increased with an increased activity level of the patient (e.g. rate adaptive pacing). For instance, the processing module 110 may monitor one or more physiological parameters of the patient which may indicate a need for an increased heart rate (e.g. due to increased metabolic demand). The processing module 110 may then increase the rate at which the pulse generator module 104 generates electrical stimulation pulses. Adjusting the rate of delivery of the electrical stimulation pulses based on the one or more physiological parameters may extend the battery life of the LCP 100 by only requiring higher rates of delivery of electrical stimulation pulses when the physiological parameters indicate there is a need for increased cardiac output. Additionally, adjusting the rate of delivery of the electrical stimulation pulses may increase a comfort level of the patient by more closely matching the rate of delivery of electrical stimulation pulses with the cardiac output need of the patient.


For ATP therapy, the processing module 110 may control the pulse generator module 104 to deliver pacing pulses at a rate faster than an intrinsic heart rate of a patient in attempt to force the heart to beat in response to the delivered pacing pulses rather than in response to intrinsic cardiac electrical signals. Once the heart is following the pacing pulses, the processing module 110 may control the pulse generator module 104 to reduce the rate of delivered pacing pulses down to a safer level. In CRT, the processing module 110 may control the pulse generator module 104 to deliver pacing pulses in coordination with another device to cause the heart to contract more efficiently. In cases where the pulse generator module 104 is capable of generating defibrillation and/or cardioversion pulses for defibrillation/cardioversion therapy, the processing module 110 may control the pulse generator module 104 to generate such defibrillation and/or cardioversion pulses. In some cases, the processing module 110 may control the pulse generator module 104 to generate electrical stimulation pulses to provide electrical stimulation therapies different than those examples described above.


Aside from controlling the pulse generator module 104 to generate different types of electrical stimulation pulses and in different sequences, in some embodiments, the processing module 110 may also control the pulse generator module 104 to generate the various electrical stimulation pulses with varying pulse parameters. For example, each electrical stimulation pulse may have a pulse width and a pulse amplitude. The processing module 110 may control the pulse generator module 104 to generate the various electrical stimulation pulses with specific pulse widths and pulse amplitudes. For example, the processing module 110 may cause the pulse generator module 104 to adjust the pulse width and/or the pulse amplitude of electrical stimulation pulses if the electrical stimulation pulses are not effectively capturing the heart. Such control of the specific parameters of the various electrical stimulation pulses may help the LCP 100 provide more effective delivery of electrical stimulation therapy.


In some embodiments, the processing module 110 may further control the communication module 102 to send information to other devices. For example, the processing module 110 may control the communication module 102 to generate one or more communication signals for communicating with other devices of a system of devices. For instance, the processing module 110 may control the communication module 102 to generate communication signals in particular pulse sequences, where the specific sequences convey different information. The communication module 102 may also receive communication signals for potential action by the processing module 110.


In further embodiments, the processing module 110 may control switching circuitry by which the communication module 102 and the pulse generator module 104 deliver communication signals and/or electrical stimulation pulses to tissue of the patient. As described above, both the communication module 102 and the pulse generator module 104 may include circuitry for connecting one or more of the electrodes 114 and/or 114′ to the communication module 102 and/or the pulse generator module 104 so those modules may deliver the communication signals and electrical stimulation pulses to tissue of the patient. The specific combination of one or more electrodes by which the communication module 102 and/or the pulse generator module 104 deliver communication signals and electrical stimulation pulses may influence the reception of communication signals and/or the effectiveness of electrical stimulation pulses. Although it was described that each of the communication module 102 and the pulse generator module 104 may include switching circuitry, in some embodiments, the LCP 100 may have a single switching module connected to the communication module 102, the pulse generator module 104, and the electrodes 114 and/or 114′. In such embodiments, processing module 110 may control the switching module to connect the modules 102/104 and the electrodes 114/114′ as appropriate.


In some embodiments, the processing module 110 may include a pre-programmed chip, such as a very-large-scale integration (VLSI) chip or an application specific integrated circuit (ASIC). In such embodiments, the chip may be pre-programmed with control logic in order to control the operation of the LCP 100. By using a pre-programmed chip, the processing module 110 may use less power than other programmable circuits while able to maintain basic functionality, thereby potentially increasing the battery life of the LCP 100. In other instances, the processing module 110 may include a programmable microprocessor or the like. Such a programmable microprocessor may allow a user to adjust the control logic of the LCP 100 after manufacture, thereby allowing for greater flexibility of the LCP 100 than when using a pre-programmed chip. In still other embodiments, the processing module 110 may not be a single component. For example, the processing module 110 may include multiple components positioned at disparate locations within the LCP 100 in order to perform the various described functions. For example, certain functions may be performed in one component of the processing module 110, while other functions are performed in a separate component of the processing module 110.


The processing module 110, in additional embodiments, may include a memory circuit and the processing module 110 may store information on and read information from the memory circuit. In other embodiments, the LCP 100 may include a separate memory circuit (not shown) that is in communication with the processing module 110, such that the processing module 110 may read and write information to and from the separate memory circuit. The memory circuit, whether part of the processing module 110 or separate from the processing module 110, may be volatile memory, non-volatile memory, or a combination of volatile memory and non-volatile memory.


The energy storage module 112 may provide a power source to the LCP 100 for its operations. In some embodiments, the energy storage module 112 may be a non-rechargeable lithium-based battery. In other embodiments, the non-rechargeable battery may be made from other suitable materials. In some embodiments, the energy storage module 112 may be considered to be a rechargeable power supply, such as but not limited to, a rechargeable battery. In still other embodiments, the energy storage module 112 may include other types of energy storage devices such as capacitors or super capacitors. In some cases, as will be discussed, the energy storage module 112 may include a rechargeable primary battery and a non-rechargeable secondary battery. In some cases, the primary battery and the second battery, if present, may both be rechargeable.


To implant the LCP 100 inside a patient's body, an operator (e.g., a physician, clinician, etc.), may fix the LCP 100 to the cardiac tissue of the patient's heart. To facilitate fixation, the LCP 100 may include one or more anchors 116. The one or more anchors 116 are shown schematically in FIG. 1. The one or more anchors 116 may include any number of fixation or anchoring mechanisms. For example, one or more anchors 116 may include one or more pins, staples, threads, screws, helix, tines, and/or the like. In some embodiments, although not shown, one or more anchors 116 may include threads on its external surface that may run along at least a partial length of an anchor member. The threads may provide friction between the cardiac tissue and the anchor to help fix the anchor member within the cardiac tissue. In some cases, the one or more anchors 116 may include an anchor member that has a cork-screw shape that can be screwed into the cardiac tissue. In other embodiments, the anchor 116 may include other structures such as barbs, spikes, or the like to facilitate engagement with the surrounding cardiac tissue.


In some examples, the LCP 100 may be configured to be implanted on a patient's heart or within a chamber of the patient's heart. For instance, the LCP 100 may be implanted within any of a left atrium, right atrium, left ventricle, or right ventricle of a patient's heart. By being implanted within a specific chamber, the LCP 100 may be able to sense cardiac electrical signals originating or emanating from the specific chamber that other devices may not be able to sense with such resolution. Where the LCP 100 is configured to be implanted on a patient's heart, the LCP 100 may be configured to be implanted on or adjacent to one of the chambers of the heart, or on or adjacent to a path along which intrinsically generated cardiac electrical signals generally follow. In these examples, the LCP 100 may also have an enhanced ability to sense localized intrinsic cardiac electrical signals and deliver localized electrical stimulation therapy. In embodiments where the LCP 100 includes an accelerometer, the LCP 100 may additionally be able to sense the motion of the cardiac wall to which the LCP 100 is attached.


While a leadless cardiac pacemaker is used as an example implantable medical device in FIG. 1, the disclosure may be applied to any suitable implantable medical device including, for example, neuro-stimulators, diagnostic devices including those that do not deliver therapy, and/or any other suitable implantable medical device as desired.



FIG. 2 is a schematic block diagram of an illustrative medical device (MD) 200 that may be used in conjunction with the LCP 100 of FIG. 1. In some cases, The MD 200 may be configured to sense physiological signals and parameters and deliver one or more types of electrical stimulation therapy to tissues of the patient. In the embodiment shown, the MD 200 may include a communication module 202, a pulse generator module 204, an electrical sensing module 206, a mechanical sensing module 208, a processing module 210, and an energy storage module 218. Each of the modules 202, 204, 206, 208, and 210 may be similar to the modules 102, 104, 106, 108, and 110 of the LCP 100. Additionally, the energy storage module 218 may be similar to the energy storage module 112 of LCP 100. However, in some embodiments, the MD 200 may have a larger volume within a housing 220. In such embodiments, the MD 200 may include a larger energy storage module 218 and/or a larger processing module 210 capable of handling more complex operations than the processing module 110 of the LCP 100.


While the MD 200 may be another leadless device such as shown in FIG. 1, in some instances the MD 200 may include leads, such as leads 212. In some instances, the leads 212 may include electrical wires that conduct electrical signals between the electrodes 214 and one or more modules located within the housing 220. In some cases, the leads 212 may be connected to and extend away from the housing 220 of the MD 200. In some embodiments, the leads 212 are implanted on, within, or adjacent to a heart of a patient. The leads 212 may contain one or more electrodes 214 positioned at various locations on the leads 212 and various distances from the housing 220. Some leads 212 may only include a single electrode 214, while other leads 212 may include multiple electrodes 214. Generally, the electrodes 214 are positioned on the leads 212 such that when the leads 212 are implanted within the patient, one or more of the electrodes 214 are positioned to perform a desired function. In some cases, the one or more of the electrodes 214 may be in contact with the patient's cardiac tissue. In other cases, the one or more of the electrodes 214 may be positioned subcutaneously but adjacent the patient's heart. The electrodes 214 may conduct intrinsically generated electrical cardiac signals to the leads 212. The leads 212 may, in turn, conduct the received electrical cardiac signals to one or more of the modules 202, 204, 206, and 208 of the MD 200. In some cases, the MD 200 may generate electrical stimulation signals, and the leads 212 may conduct the generated electrical stimulation signals to the electrodes 214. The electrodes 214 may then conduct the electrical stimulation signals to the cardiac tissue of the patient (either directly or indirectly). The MD 200 may also include one or more electrodes 214 not disposed on a lead 212. For example, one or more electrodes 214 may be connected directly to the housing 220.


The leads 212, in some embodiments, may additionally contain one or more sensors, such as accelerometers, blood pressure sensors, heart sound sensors, blood-oxygen sensors, and/or other sensors which are configured to measure one or more physiological parameters of the heart and/or patient. In such embodiments, the mechanical sensing module 208 may be in electrical communication with the leads 212 and may receive signals generated from such sensors. In some cases, one or more of these additional sensors may instead be incorporated into or onto the MD 200.


While not required, in some embodiments the MD 200 may be an implantable medical device. In such embodiments, the housing 220 of MD 200 may be implanted in, for example, a transthoracic region of the patient. The housing 220 may generally include any of a number of known materials that are safe for implantation in a human body and may, when implanted, hermetically seal the various components of the MD 200 from fluids and tissues of the patient's body. In such embodiments, the leads 212 may be implanted at one or more various locations within the patient, such as within the heart of the patient, adjacent to the heart of the patient, adjacent to the spine of the patient, or any other desired location.


In some embodiments, the MD 200 may be an implantable cardiac pacemaker (ICP). In these embodiments, the MD 200 may have one or more leads, for example leads 212, which are implanted on or within the patient's heart. The one or more leads 212 may include one or more electrodes 214 that are in contact with cardiac tissue and/or blood of the patient's heart. The MD 200 may be configured to sense intrinsically generated cardiac electrical signals and determine, for example, one or more cardiac arrhythmias based on analysis of the sensed signals. The MD 200 may be configured to deliver CRT, ATP therapy, bradycardia therapy, and/or other therapy types via the leads 212 implanted within the heart. In some embodiments, the MD 200 may additionally be configured to provide defibrillation/cardioversion therapy.


In some instances, the MD 200 may be an implantable cardioverter-defibrillator (ICD). In such embodiments, the MD 200 may include one or more leads implanted within a patient's heart. The MD 200 may also be configured to sense electrical cardiac signals, determine occurrences of tachyarrhythmia's based on the sensed electrical cardiac signals, and deliver defibrillation and/or cardioversion therapy in response to determining an occurrence of a tachyarrhythmia (for example by delivering defibrillation and/or cardioversion pulses to the heart of the patient). In other embodiments, the MD 200 may be a subcutaneous implantable cardioverter-defibrillator (SICD). In embodiments where the MD 200 is an SICD, one of the leads 212 may be a subcutaneously implanted lead. In at least some embodiments where the MD 200 is an SICD, the MD 200 may include only a single lead which is implanted subcutaneously but outside of the chest cavity, however this is not required. In some cases, the lead may be implanted just under the chest cavity.


In some embodiments, the MD 200 may not be an implantable medical device. Rather, the MD 200 may be a device external to the patient's body, and the electrodes 214 may be skin-electrodes that are placed on a patient's body. In such embodiments, the MD 200 may be able to sense surface electrical signals (e.g. electrical cardiac signals that are generated by the heart or electrical signals generated by a device implanted within a patient's body and conducted through the body to the skin). The MD 200 may further be configured to deliver various types of electrical stimulation therapy, including, for example, defibrillation therapy via skin-electrodes 214.


In some cases, implantable medical devices such as the IMD 100 and/or the MD 200 devote a substantial portion of their internal volume to energy storage. It will be appreciated that the life expectancy of an implanted device depends in large part upon the life expectancy of the battery powering the implanted device. Accordingly, there are competing interests in wanting to maximize battery life (and hence device life expectancy) while making implanted devices as small as possible in order to facilitate delivery using various techniques such as trans-catheter delivery as well as to make the implanted devices less intrusive. In some cases, such as for implanted devices intended to be implanted in particular chambers of the heart, there are additional potential size limitations. A device that is too large in diameter may be difficult to deliver while a device that is too long may interfere with the operation of the valve (e.g. interfere with the valve, interfere with blood flow, etc.).


Accordingly, some implanted devices such as but not limited to a leadless cardiac pacemaker (LCP) may be configured to include a rechargeable battery that provides the power needed by the LCP for a limited period of time. Because the rechargeable battery can be recharged in situ, the rechargeable battery can be smaller because it does not have to store sufficient energy to last the entire expected lifetime of the device. Rather, the rechargeable battery only needs to store sufficient energy to power the LCP for a period of time that corresponds to a reasonable recharging schedule. For example, a LCP with a rechargeable battery may undergo a recharging procedure on a daily basis, a weekly basis, a monthly basis, a by-yearly basis, a yearly basis, or any desired schedule, with the recognition that relative size of the rechargeable battery is at least roughly proportional to the interval between rechargings. For example, a relatively small rechargeable battery will take up less space within the LCP but will require more frequent recharging. A relatively large rechargeable battery will take up more space within the LCP but will require less frequent recharging as the larger rechargeable battery can store relatively more chemical energy. In some cases, the battery size may be roughly inversely proportional to the frequency of the impinging energy that is captured and used to recharge the rechargeable battery.


In some cases, an implanted device with a rechargeable battery may be implanted within a patient. In the case of an LCP with a rechargeable battery, the LCP may be implanted within a chamber of the patient's heart. The patient may periodically undergo a recharging procedure in which energy from outside of the patient may be transmitted to the LCP (or other implanted device) within the patient. In some cases, the LCP or other implanted device may include an antenna or other structure that is configured to receive the transmitted energy and the received energy may be used to at least partially recharge the rechargeable battery. It will be appreciated that at least partially recharging the rechargeable battery may, for example, mean recharging the rechargeable battery to capacity. It may mean recharging the rechargeable battery to a charge level that is less than capacity. For example, recharging the rechargeable battery may mean recharging to a charge level that is about 50 percent (%) of capacity, about 60% of capacity, about 70% of capacity, about 80% of capacity, or about 90% of capacity.



FIG. 3 provides a highly schematic illustration of a patient 300 having an implantable device 302 implanted within the patient 300. While the implantable device 302 is shown as being in or near the patient's chest, it will be appreciated that this is merely illustrative, as the implantable device 302, depending on functionality, may be implanted in other locations within the patient 300. A transmitter 304 is shown exterior to the patient 300. In some cases, the transmitter 304 may be configured to transmit electromagnetic (EM) radiative energy that is of a wavelength (or frequency, as wavelength and frequency are related by the numerical speed of light) and intensity that can safety pass into the patient 300 to the implantable device 302 without causing excessive tissue heating or other potentially damaging effects to the patient 300.


The transmitter 304 may take any of a variety of forms. For example, while shown schematically as a box in FIG. 3, the transmitter 304 may be sized and configured for the patient 300 to periodically wear about their neck on a lanyard, which would place the transmitter 304 proximate their chest, at about the same vertical and horizontal position as the implantable device 302 within the patient's chest. In some cases, for example, the transmitter 304 may be built into the back of a chair that the patient 300 would periodically sit in to recharge the implantable device 302. The chair could be in the patient's home, for a daily recharge, for example, or could be at a remote location such as a medical clinic, for a patient 300 having a longer recharge schedule. As another example, the transmitter 304 could be built into a bed such that the transmitter 304 could at least partially recharge the implantable device 302 each evening when the patient 300 sleeps. In some cases, the transmitter 304 could be configured to only transmit once per week, or once per month, for example, depending on the power requirements of the implantable device 302. In some cases, the transmitter 304 and the implantable device 302 may communicate with each other. When so provided, the implantable device 302 may report its current battery recharge level to the transmitter 304, and if the current battery recharge level is below a threshold, the transmitter 304 may transmit power to the implantable device 302.


It will be appreciated that the implantable device 302 may be configured to periodically receive EM energy at a wavelength and intensity that is safe for the patient 300 and that the implantable device 302 may use to recharge a rechargeable battery within the implantable device 302. The EM energy may be received at a rate that exceeds a rate at which power is being drawn from the rechargeable battery and consumed by various components within the implantable device 302.



FIG. 4 provides an illustrative but non-limiting example of at least some of the internal components within the implantable device 302. In some cases, the implantable device 302 includes a device housing 306. In some cases, the device housing 306 may include at least a portion thereof that is formed of a material that is transparent or at least substantially transparent to the EM energy that is being transmitted from the transmitter 304 to the implantable device 302. In this, “substantially” transparent may be defined, for example, as allowing at least 70%, or at least 80%, at least 90%, or at least 95% of incident energy at a particular wavelength (or range of wavelengths) to pass through the material without being absorbed by the material or blocked by the material. For example, at least a portion of the device housing 306, or even all of the device housing 306, may be made of a material such as glass or a ceramic. To illustrate, perhaps a first portion 306a of the device housing 306, which overlays a receiving antenna 308, may be made of a material that is transparent or at least substantially transparent to the EM energy that is being transmitted from the transmitter 304 while a second portion 306b of the device housing 306, which does not overlay the receiving antenna 308, may be made of other materials such as but not limited to metals which could otherwise interference with EM energy transmitted from the transmitter 304 reaching the receiving antenna 308. In some cases, both the first portion 306a and the second portion 306b may be made of a material that is transparent or at least substantially transparent to the EM energy that is being transmitted from the transmitter 304.


The receiving antenna 308 may be any of a variety of different types of antennas. In some cases, the receiving antenna 308 may be a planar antenna, which in some cases is then conformed to a non-planar surface. In some cases, a planar antenna may be an antenna that is printed or deposited onto a planar surface, or perhaps etched into a planar surface. In some instances, depending on how the receiving antenna 308 is incorporated into the implantable device 302, the receiving antenna 308 may be considered as being a three-dimensional analog of a planar antenna (e.g. conformed to a non-planar shape). Illustrative but non-limiting examples of planar antennas include path antennas, slot antennas, ring antennas, spiral antennas, bow-tie antennas, TSA (Vivaldi) antennas, LPDA antennas, leaky-wave antennas and quasi-yagi antennas. In some cases, the antenna may include a resonator structure that helps to make the antenna more efficient and/or to increase an effective electrical length of the antenna such that the antenna may be made physically smaller.


EM energy that is transmitted from the transmitter 304 may be captured by the receiving antenna 308 and provided to a circuitry 310. In some cases, the circuitry 310 may be configured to convert the received EM energy into a form that may be used to recharge a rechargeable battery 312. In some cases, the circuitry 310 may also provide other functionality to the implantable device 302. For example, if the implantable device 302 is an LCP, the circuitry 310 may, in addition to recharging the rechargeable battery 312, also provide sense functions, pace functions, or sense and pace functions. In some instances, the circuitry 310 only functions to recharge the rechargeable battery 312, and the implantable device 302 may include other circuitry (not shown) to provide whichever other functions are ascribed to the implantable device 302.


When considering the electromagnetic regions around a transmitting antenna, there are three categories; namely, (1) reactive near-field; (2) radiated near-field and (3) radiated far-field. “Inductive” charging systems operate in the reactive near-field region. In inductive power systems, power is typically transferred over short distances by magnetic fields using inductive coupling between coils of wire, or by electric fields using capacitive coupling between electrodes. In radiative power systems (e.g. radiated near-field and radiated far-field), power is typically transmitted by beams of electromagnetic (EM) energy. Radiative power systems can often transport energy for longer distances, but the ability of a receiving antenna to capture sufficient energy can be challenging, particular for applications where the size of the receiving antenna is limited.


In some cases, the transmitter 304 and implantable medical device 302 may operate at or above about 400 MHz within the patient's body. When so provided, the system does not operate in the reactive near-field (as in inductive charging system), but rather operates in either the radiated near-field or radiated far-field regions (depending on the placement of the implanted device and band of usage). For example, when the EM energy is transmitted at 400 MHz, the system is in the radiated near-field region and at 2.45 GHz the system is in the radiated far-field region. In some cases, the present system may operate at a frequency that is between, for example, about 400 MHz and 3 GHz. In some cases, more than one frequency within this range may be used simultaneously and/or sequentially. In some cases, multiple implanted devices may be simultaneously or sequentially charged using both the radiated near-field and radiated far-field regions.


The rechargeable battery 312 may be any type of rechargeable battery 312, and may take a three dimensional shape that facilitates incorporation of the rechargeable battery 312 into the device housing 304. In some cases, the rechargeable battery 312 may instead be a supercapacitor. As will be appreciated, in some cases the device housing 304 may have a cylindrical or substantially cylindrical shape, in which case a rechargeable battery 312 having an cylindrical or annular profile, such as a button battery or an elongated (in height) battery having a substantially cylindrical shape, may be useful. It is recognized that there are possible tradeoffs in rechargeable battery shape and dimensions relative to performance, so these issues should be considered in designing the rechargeable battery 312 for a particular use. While FIG. 4 schematically shows a single rechargeable battery 312, in some cases there may be two, three or more distinct rechargeable batteries 312, each electrically coupled with the circuitry 310. For example, in some cases there may be performance advantages in having multiple rechargeable batteries 312. In some instances, there may be packaging advantages to having multiple (and smaller) rechargeable batteries 312.



FIG. 5 provides a schematic view of an IMD 320 that may be configured to be implanted within a patient such as the patient 300 (FIG. 3). The illustrative IMD 320 includes a housing 322 that is substantially transparent to EM energy such as radiative EM energy along at least part of its length. For example, in some cases, a first portion 322a of the housing 322 may be substantially transparent to radiative EM energy while a second portion 322b of the housing 320 may be less transparent to radiative EM energy. In some cases, the second portion 322b of the housing 320 may also be substantially transparent to radiative EM energy. In some cases, at least the first portion 322a of the housing 320 may be ceramic or glass. Circuitry 310 may be disposed within the housing 320. In some cases, as described with respect to FIG. 4, the circuitry 310 may be mono-functional, meaning its only function is for recharging, or the circuitry 310 may be multi-functional, meaning that the circuitry 310 has additional functionality beyond recharging.


In some cases, a first electrode 324 and a second electrode 326 may be exposed external to the housing 320 and may be operably coupled to the circuitry 310. While two electrodes are illustrated, it will be appreciated that in some instances the IMD 320 may include three, four or more distinct electrodes. Depending on the intended functionality of the IMD 320, the first electrode 324 and the second electrode 326, in combination, may be used for sensing and/or pacing the patient's heart. In some instances, for example, the IMD 320 may be a leadless cardiac pacemaker (LCP), an implantable monitoring device or an implantable sensor. In some cases, the first electrode 324 and the second electrode 326 may, in combination, be used for communicating with other implanted devices and/or with external devices. In some cases, communication with other implanted devices may include conductive communication, but this is not required. Rechargeable battery 312 may be disposed within the housing 320 and may be configured to power the IMD 320, including the circuitry 310.


Receiving antenna 308 may be disposed within the housing 320 and may be configured to receive transmitted radiative EM energy through the housing 320, such as through the first portion 322a of the housing 320 that is substantially transparent to radiative EM energy. The circuitry 310 may be operably coupled with the receiving antenna 308 and the rechargeable battery 312. In some cases, the circuitry 310 may be configured to charge the rechargeable battery 312 using the radiative EM energy received by the receiving antenna 308. In some cases, the receiving antenna 308 may be configured to receive sufficient radiative EM energy from a wavelength band of radiative EM energy transmitted from outside the patient 300 (FIG. 3) to recharge the rechargeable battery 312 at a rate faster than the rechargeable battery 312 is depleted by powering the IMD 320 when the wavelength band of radiative EM energy is transmitted at an intensity that does not cause heat damage to the patient 300. In some cases, the housing 320 has a substantially cylindrical profile and the receiving antenna 308 includes a planar antenna that has been conformed to the substantially cylindrical profile of an inner surface of an inner cavity defined by the housing 320.



FIG. 6 provides a schematic view of an IMD 340 that may be configured to be implanted within a patient such as the patient 300 (FIG. 3). The illustrative IMD 340 includes a housing 342 that may be configured for trans-catheter deployment. In some cases, this means that the housing 342 has overall dimensions that enable the IMD 340 to fit within a catheter or similar device for delivering the IMD 340 via a vascular approach. In some cases, the housing 342 may have an overall length of perhaps about five centimeters or less, or perhaps about three centimeters or less, and/or an overall width of perhaps about 2 centimeters or less, or perhaps about 1 centimeter or less. In some cases, for example, the housing 342 may also be substantially transparent to EM energy such as radiative EM energy along at least part of its length. For example, in some cases, a first portion 342a of the housing 342 may be substantially transparent to radiative EM energy while a second portion 342b of the housing 342 may be less transparent to radiative EM energy. In some cases, the second portion 342b of the housing 342 may also be substantially transparent to radiative EM energy. In some cases, at least the first portion 342a of the housing 342 may be ceramic or glass. In some cases, the housing 342 (or portions thereof) may be a ceramic housing, a glass housing or a polymeric housing.


While the illustrative IMD 320 (FIG. 5) included a single circuitry 310, which could be mono-functional or multi-functional, in some cases the IMD 340 (FIG. 6) includes charging circuitry 344 and therapeutic circuitry 346. In some cases, the charging circuitry 344 and the therapeutic circuitry 346 may be located on distinct circuit boards or be manifested within distinct integrated circuits (ICs). In some cases, the charging circuitry 344 and the therapeutic circuitry 346, while shown as distinct elements, may be combined within a single IC or on a single circuit board. The charging circuitry 344 may be operably coupled with the receiving antenna 308 and the rechargeable battery 312, and may be configured to use the radiative EM energy received by the receiving antenna 308 to charge the rechargeable battery 312.


In some cases, the IMD 340 may include a secondary battery 348 that is disposed within the housing 342 and that is operably coupled to the therapeutic circuitry 346. In some cases, the secondary battery 348 may function as a backup battery to the rechargeable battery 312. In some instances, the secondary battery 348 may also be a rechargeable battery and thus may also be operably coupled with the charging circuitry 344. In some cases, the secondary battery 348 may be a non-rechargeable battery.


In some cases, the therapeutic circuitry 346 may be operatively coupled to the first electrode 324 and the second electrode 326. While two electrodes are illustrated, it will be appreciated that in some instances the IMD 340 may include three, four or more distinct electrodes. In some instances, the therapeutic circuitry 346 may be configured to sense one or more signals via the electrodes 324, 326 (or additional electrodes) and/or to stimulate tissue via the electrodes 324, 326. In some cases, the therapeutic circuitry 346 may pace, or stimulate tissue, at least partly in response to the one or more sensed signals. In some cases, the first electrode 324 and the second electrode 326 may, in combination, be used for communicating with other implanted devices and/or with external devices. In some cases, communication with other implanted devices may include conductive communication, but this is not required in all cases.



FIG. 7 is a schematic cross-sectional side view of an illustrative LCP 400 having a rechargeable battery. The illustrative LCP 400 has a housing 402 that is formed of a ceramic material, a glass material or perhaps a polymeric material. It will be appreciated, therefore, that the housing 402 is at least substantially transparent to radiative EM energy that is incident upon the LCP 400. The housing 402 defines an interior volume 404 that houses a variety of different components, including but not limited to circuitry 406 and a rechargeable battery 408. In some cases the circuitry 406 may be limited to recharging the rechargeable battery 408. In some instances, the circuitry 406 may also have additional functionality such as sensing and/or pacing, although in some cases the LCP 400 may include additional circuitry for additional functionality. In some cases, the circuitry 406 is operably coupled with a first electrode 420 and one or more other electrodes (not shown).


A receiving antenna 410 is operably coupled to the circuitry 406. In some cases, as illustrated, the housing 402 itself may form at least one or more layers of the receiving antenna 410. In some cases, the receiving antenna 410 includes an outer metal layer 412 and an inner metal layer 414, connected by a via 416 extending through an aperture 418 in the housing 402 wall. While the outer metal layer 412 and the inner metal layer 414 are schematically illustrated as simple layers, it will be appreciated that in some cases the outer metal layer 412 and/or the inner metal layer 414 may include patterns within the metal. The outer metal layer 412 and/or the inner metal layer 414 may, for example, be formed by etching away portions of a base metal layer. In some cases, the outer metal layer 412 and/or the inner metal layer 414 may be formed via a deposition process. In some cases, the ceramic or other material forming the housing 402 may function as a dielectric layer between the outer metal layer 412 and the inner metal layer 414.


In some cases, a biocompatible polymeric layer 422 may cover the outer metal layer 412. The biocompatible polymeric layer 422 may, for example, be formed of a polyimide or Parylene. In some cases, depending on the exact material used to form the housing 402, and whether the exact material is biocompatible, a polymeric coating (not shown) may cover essentially all of the outer surface of the housing 402 in order to improve biocompatibility. In some instances, particularly if the housing 402 is formed of a material having any porosity, a polymeric covering may help to reduce porosity.


In some cases, and as shown in FIG. 7, the receiving antenna 410 may be built right into the housing 402 of the LCP 400. In some cases, however, the receiving antenna may be formed in or on a first structure that can subsequently be inserted into or advanced over a device housing. For example, FIG. 8 shows a sleeve insert that can be inserted into a device housing, and FIG. 9 shows an outer sleeve that can be disposed over a device housing.


More specifically, FIG. 8 shows a sleeve insert 500 that is configured to be insertable into a device housing 502. The device housing 502 includes an elongated cavity 504 that is configured to accommodate the sleeve insert 500 therein. While the elongated cavity 504 is illustrated as generally being an entire interior space of the device housing 502, it will be appreciated that in some cases the interior of the device housing 502 may be divided into compartments, and the elongated cavity 504 may be one of those compartments. The sleeve insert 500 may be considered as having an outer surface 506 and an inner surface 508. A receiving antenna 510 may be built into the sleeve insert 500. In some cases, the receiving antenna 510 includes a first metal pattern 512 that is formed on the outer surface 506 and a second metal pattern 514 that is formed on the inner surface 508. The material forming the sleeve insert 500 may, for example, include a dielectric layer and may itself form part of the receiving antenna 510. In some cases, the first metal pattern 512 and the second metal layer 514 may form an antenna with a resonator. The device housing 502 may be at least substantially transparent to radiative EM energy to allow the radiative EM energy to reach the receiving antenna 510.



FIG. 9 shows an outer sleeve 516 that is configured to fit over a device housing 518. In some cases, the outer sleeve 516 may be considered as having an outer surface 520 and an inner surface 522. The outer sleeve 516 may include a receiving antenna 524 that is built into the outer sleeve 516. In some cases, for example, the receiving antenna 524 may include a first metal pattern 526 that is formed on the outer surface 520 and a second metal pattern 528 that is formed on the inner surface 522. The material forming the outer sleeve 516 may, for example, include a dielectric layer and may itself form part of the receiving antenna 524. In some cases, the first metal pattern 526 and the second metal layer 528 may form an antenna with a resonator. In this embodiment, the device housing 518 need not be substantially transparent to radiative EM energy since the radiative EM energy need not travel through the device housing 518 to reach the receiving antenna 524.



FIGS. 10 through 12 provide illustrative but non-limiting examples of receiving antenna patterns. It will be appreciated that these patterns (and others) may be built directly into a device housing, as shown for example in the LCP 400 of FIG. 7. In some cases, these patterns (and others) may be used in building a sleeve insert such as the sleeve insert 500 (FIG. 8). In some instances, these patterns (and others) may be used in building an outer sleeve such as the outer sleeve 516. FIGS. 10-12 illustrate a cylindrical form 600 that may, for example, represent a sleeve insert or an outer sleeve, or perhaps a device housing. While shown as a cylinder, it will be appreciated that the cylindrical form 600 may take any desired shape, size or configuration.


The cylindrical form 600 includes an outer surface 602. In FIG. 10, a first receiving antenna 604 and a second receiving antenna 606 are shown disposed relative to the outer surface 602. The receiving antenna 604 and the receiving antenna 606 may, for example, be formed entirely on the outer surface 602. In some cases, the receiving antenna 604 and the receiving antenna 606 may be formed with components on the outer surface 602 and components interior to the cylindrical form 600 (e.g. antenna with a resonator).


While two receiving antennae 604 and 606 are shown, the device may include any number of receiving antennae. FIG. 11, for example, is a schematic cross-sectional view showing a total of four receiving antennae 608, 610, 612, 614, with each receiving antenna constructed with a first metal pattern 616, 618, 620, 622 disposed on the outer surface 602 and a corresponding second metal pattern 624, 626, 628, 630 disposed on an inner surface 632, with vias 634, 636, 638, 640 extending between the first metal pattern 616, 618, 620, 622 and the second metal pattern 624, 626, 628, 630.



FIG. 12 illustrates a receiving antenna 642 that is laid out in a helical or spiral pattern relative to the outer surface 602. The receiving antenna 642 may, for example, be formed entirely on the outer surface 602. In some cases, the receiving antenna 524 may be formed with components on the outer surface 602 and components interior to the cylindrical form 600. While indicated as a single helical receiving antenna 642, in some cases the receiving antenna 642 may instead have distinct segments, such as a segment 642a, a segment 642b and a segment 642c.


It will be appreciated that in some cases, an antenna such as a receiving antenna may have a null such as a spatial null and/or a frequency null. A spatial null indicates a direction from which no signal or very little signal may be received. A frequency null indicates a particular frequency or range of frequencies for which no signal or very little signal may be received. In some cases, if a device such as an implantable device includes two or more receiving antennae, it will be appreciated that each antenna may have a spatial null. There may be advantages to laying out the two or more receiving antenna such that the spatial nulls do not align in space. This may be particularly useful in an implantable device, in which the exact implanted orientation of the device is uncertain and/or may change with time. In many cases, particularly if the implantable device is planted in or on the heart, the device is constant moving. FIGS. 13 and 14 provide several illustrative but non-limiting examples of how antennae may be laid out in order to intentionally miss-align their respective spatial nulls.


In FIG. 13, a first receiving antenna 650 is laid out relative to the outer surface 602 of the cylindrical form 600, oriented at a first angle relative to a longitudinal axis 648. A second receiving antenna 652 is laid out relative to the outer surface 602, oriented at a second angle relative to the longitudinal axis 648, with the first angle being different from the second angle. In FIG. 14, a first receiving antenna 654 is laid out relative to the outer surface 602, oriented roughly perpendicular to the longitudinal axis 648. A second receiving antenna 656 is laid out relative to the outer surface 602, oriented roughly parallel with the longitudinal axis 648. It will be appreciated that one or more of the receiving antennae 650, 652, 654, 656 may, for example, be formed entirely on the outer surface 602. In some cases, one or more of the receiving antennae 650, 652, 654, 656 may be formed with components on the outer surface 602 and components interior to the cylindrical form 600. It will also be appreciated that the angles shown in FIGS. 13 and 14 are merely illustrative.


It should be understood that this disclosure is, in many respects, only illustrative. Changes may be made in details, particularly in matters of shape, size, and arrangement of steps without exceeding the scope of the disclosure. This may include, to the extent that it is appropriate, the use of any of the features of one example embodiment being used in other embodiments.

Claims
  • 1. An implantable medical device (IMD) configured to be implanted within a patient, the IMD comprising: a housing having a wall that defines an elongated cavity, the housing configured for trans-catheter deployment;a plurality of electrodes exposed external to the housing;therapeutic circuitry disposed within the elongated cavity of the housing, the therapeutic circuitry operatively coupled to the plurality of electrodes and configured to sense one or more signals via one or more of the plurality of electrodes and/or to stimulate tissue via one or more of the plurality of electrodes;a rechargeable power source disposed within the elongated cavity of the housing and configured to power the therapeutic circuitry;a receiving antenna disposed relative to the housing and configured to receive transmitted radiative Electro-Magnetic (EM) energy through the patient's body that is transmitted at a frequency between about 400 MHz and about 3 GHz, the receiving antenna comprising a first metal pattern disposed on an inner curved surface of an elongate annular dielectric sleeve and a second metal pattern disposed on an outer curved surface of the elongate annular dielectric sleeve, wherein the elongate annular dielectric sleeve is coaxially aligned with and extends longitudinally along the housing, is shaped to conform along the wall of the housing, and encircles at least a portion of at least one of the therapeutic circuitry and the rechargeable power source, and wherein the first metal pattern, the second metal pattern and the elongate annular dielectric sleeve together form the receiving antenna; andcharging circuitry operably coupled with the receiving antenna and the rechargeable power source, the charging circuitry configured to use the radiative EM energy received via the receiving antenna to charge the rechargeable power source.
  • 2. The IMD of claim 1, further comprising a secondary battery disposed within the housing and operatively coupled to the therapeutic circuitry, the secondary battery functioning as a backup battery to the rechargeable power source.
  • 3. The IMD of claim 2, wherein the secondary battery is a non-rechargeable battery.
  • 4. The IMD of claim 1, wherein the IMD comprises a leadless cardiac pacemaker (LCP).
  • 5. The IMD of claim 1, wherein the housing is substantially transparent to radiative EM energy.
  • 6. The IMD of claim 5, wherein the housing comprises a ceramic housing, a glass housing, or a polymeric housing.
  • 7. The IMD of claim 5, wherein the elongate annular dielectric sleeve is substantially cylindrical and is inserted into the elongated cavity of the housing of the IMD, conforms along an inner surface of the wall of the housing, and encircles at least a portion of at least one of the therapeutic circuitry and the rechargeable power source.
  • 8. The IMD of claim 1, wherein the elongate annular dielectric sleeve is substantially cylindrical and fits over the outside of the housing, conforms to an outer surface of the wall of the housing, and is secured relative to the housing of the IMD.
  • 9. The IMD of claim 1, wherein the at least one of the plurality of electrodes forms part of the receiving antenna.
  • 10. An implantable medical device (IMD) configured to be implanted within a patient, the IMD comprising: an elongated housing that is substantially transparent to radiative Electro-Magnetic (EM) energy along at least part of its length;circuitry disposed within the housing;a plurality of electrodes exposed external to the housing and operatively coupled to the circuitry;a rechargeable power source disposed within the housing and configured to power the IMD including the circuitry;a receiving antenna disposed within the housing and configured to receive transmitted radiative EM energy through the at least part of the housing that is substantially transparent to radiative EM energy, the receiving antenna includes a first metal pattern that is formed on an inner surface of an elongate annular sleeve and a second metal pattern that is formed on an outer surface of the elongated annular sleeve, the elongate annular sleeve wrapping around at least a portion of at least one of the circuitry and the rechargeable power source; andthe circuitry operably coupled with the receiving antenna and the rechargeable power source, the circuitry configured to use the radiative EM energy received via the receiving antenna to charge the rechargeable power source;wherein at least a portion of the housing has a substantially cylindrical profile and the receiving antenna also has a substantially cylindrical profile.
  • 11. The IMD of claim 10, wherein the IMD comprises a leadless cardiac pacemaker (LCP).
  • 12. The IMD of claim 10, wherein the IMD comprises an implantable monitoring device.
  • 13. The IMD of claim 10, wherein the IMD comprises an implantable sensor.
  • 14. The IMD of claim 10, wherein the receiving antenna comprises a first receiving antenna having a first null and a second receiving antenna having a second null offset from the first null.
  • 15. The IMD of claim 10, wherein the housing comprises ceramic.
  • 16. The IMD of claim 10, wherein the housing comprises glass.
  • 17. The IMD of claim 10, wherein the receiving antenna is configured to receive sufficient radiative EM energy from a wavelength band of radiative EM energy transmitted from outside the patient to recharge the rechargeable power source at a rate faster than the rechargeable power source is depleted by powering the IMD when the wavelength band of radiative EM energy is transmitted at an intensity that does not cause heat damage to the patient.
  • 18. An implantable medical device (IMD) configured to be implanted within a patient, the IMD comprising: a housing having an elongated cavity, the housing forming one or more layers of a multiple layer receiving antenna, wherein the multiple layer receiving antenna is configured to receive transmitted radiative Electro-Magnetic (EM) energy through the patient's body;a plurality of electrodes exposed external to the housing;circuitry disposed within the elongated cavity of the housing, the circuitry operatively coupled to the plurality of electrodes and configured to sense one or more signals via one or more of the plurality of electrodes and/or to stimulate tissue via one or more of the plurality of electrodes;a rechargeable power source disposed within the elongated cavity of the housing and configured to power the circuitry;charging circuitry disposed within the elongated cavity of the housing and operably coupled with the multiple layer receiving antenna and the rechargeable power source, the charging circuitry configured to use the radiative EM energy received via the multiple layer receiving antenna to charge the rechargeable power source; andwherein the multiple layer receiving antenna at least partially surrounds the circuitry, the rechargeable power source and/or the charging circuitry.
CROSS REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of U.S. Provisional Patent Application Ser. No. 62/316,158 filed on Mar. 31, 2016, the disclosure of which is incorporated herein by reference.

US Referenced Citations (1122)
Number Name Date Kind
3835864 Rasor et al. Sep 1974 A
3943936 Rasor et al. Mar 1976 A
4142530 Wittkampf Mar 1979 A
4151513 Menken et al. Apr 1979 A
4157720 Greatbatch Jun 1979 A
RE30366 Rasor et al. Aug 1980 E
4243045 Maas Jan 1981 A
4250884 Hartlaub et al. Feb 1981 A
4256115 Bilitch Mar 1981 A
4263919 Levin Apr 1981 A
4310000 Lindemans Jan 1982 A
4312354 Walters Jan 1982 A
4323081 Wiebusch Apr 1982 A
4357946 Dutcher et al. Nov 1982 A
4365639 Goldreyer Dec 1982 A
4440173 Hudziak et al. Apr 1984 A
4476868 Thompson Oct 1984 A
4522208 Buffet Jun 1985 A
4537200 Widrow Aug 1985 A
4556063 Thompson et al. Dec 1985 A
4562841 Brockway et al. Jan 1986 A
4593702 Kepski et al. Jun 1986 A
4593955 Leiber Jun 1986 A
4630611 King Dec 1986 A
4635639 Hakala et al. Jan 1987 A
4674508 DeCote Jun 1987 A
4712554 Garson Dec 1987 A
4729376 DeCote Mar 1988 A
4754753 King Jul 1988 A
4759366 Callaghan Jul 1988 A
4776338 Lekholm et al. Oct 1988 A
4787389 Tarjan Nov 1988 A
4793353 Borkan Dec 1988 A
4819662 Heil et al. Apr 1989 A
4858610 Callaghan et al. Aug 1989 A
4886064 Strandberg Dec 1989 A
4887609 Cole, Jr. Dec 1989 A
4928688 Mower May 1990 A
4967746 Vandegriff Nov 1990 A
4987897 Funke Jan 1991 A
4989602 Sholder et al. Feb 1991 A
5012806 De Bellis May 1991 A
5036849 Hauck et al. Aug 1991 A
5040534 Mann et al. Aug 1991 A
5058581 Silvian Oct 1991 A
5078134 Heilman et al. Jan 1992 A
5109845 Yuuchi et al. May 1992 A
5113859 Funke May 1992 A
5113869 Nappholz et al. May 1992 A
5117824 Keimel et al. Jun 1992 A
5127401 Grevious et al. Jul 1992 A
5133353 Hauser Jul 1992 A
5144950 Stoop et al. Sep 1992 A
5170784 Ramon et al. Dec 1992 A
5179945 Van Hofwegen et al. Jan 1993 A
5193539 Schulman et al. Mar 1993 A
5193540 Schulman et al. Mar 1993 A
5241961 Henry Sep 1993 A
5243977 Trabucco et al. Sep 1993 A
5259387 dePinto Nov 1993 A
5269326 Verrier Dec 1993 A
5284136 Hauck et al. Feb 1994 A
5300107 Stokes et al. Apr 1994 A
5301677 Hsung Apr 1994 A
5305760 McKown et al. Apr 1994 A
5312439 Loeb May 1994 A
5313953 Yomtov et al. May 1994 A
5314457 Jeutter et al. May 1994 A
5314459 Swanson et al. May 1994 A
5318597 Hauck et al. Jun 1994 A
5324316 Schulman et al. Jun 1994 A
5331966 Bennett et al. Jul 1994 A
5334222 Salo et al. Aug 1994 A
5342408 Decoriolis et al. Aug 1994 A
5370667 Alt Dec 1994 A
5372606 Lang et al. Dec 1994 A
5376106 Stahmann et al. Dec 1994 A
5383915 Adams Jan 1995 A
5388578 Yomtov et al. Feb 1995 A
5404877 Nolan et al. Apr 1995 A
5405367 Schulman et al. Apr 1995 A
5411031 Yomtov May 1995 A
5411525 Swanson et al. May 1995 A
5411535 Fujii et al. May 1995 A
5456691 Snell Oct 1995 A
5458622 Alt Oct 1995 A
5466246 Silvian Nov 1995 A
5468254 Hahn et al. Nov 1995 A
5472453 Alt Dec 1995 A
5522866 Fernald Jun 1996 A
5540727 Tockman et al. Jul 1996 A
5545186 Olson et al. Aug 1996 A
5545202 Dahl et al. Aug 1996 A
5571146 Jones et al. Nov 1996 A
5591214 Lu Jan 1997 A
5620466 Haefner et al. Apr 1997 A
5634938 Swanson et al. Jun 1997 A
5649968 Alt et al. Jul 1997 A
5662688 Haefner et al. Sep 1997 A
5674259 Gray Oct 1997 A
5683426 Greenhut et al. Nov 1997 A
5683432 Goedeke et al. Nov 1997 A
5706823 Wodlinger Jan 1998 A
5709215 Perttu et al. Jan 1998 A
5720770 Nappholz et al. Feb 1998 A
5728154 Crossett et al. Mar 1998 A
5741314 Daly et al. Apr 1998 A
5741315 Lee et al. Apr 1998 A
5752976 Duffin et al. May 1998 A
5752977 Grevious et al. May 1998 A
5755736 Gillberg et al. May 1998 A
5759199 Snell et al. Jun 1998 A
5774501 Halpern et al. Jun 1998 A
5792195 Carlson et al. Aug 1998 A
5792202 Rueter Aug 1998 A
5792203 Schroeppel Aug 1998 A
5792205 Alt et al. Aug 1998 A
5792208 Gray Aug 1998 A
5814089 Stokes et al. Sep 1998 A
5827216 Igo et al. Oct 1998 A
5836985 Goyal et al. Nov 1998 A
5836987 Baumann et al. Nov 1998 A
5842977 Lesho et al. Dec 1998 A
5855593 Olson et al. Jan 1999 A
5873894 Vandegriff et al. Feb 1999 A
5891184 Lee et al. Apr 1999 A
5897586 Molina Apr 1999 A
5899876 Flower May 1999 A
5899928 Sholder et al. May 1999 A
5919214 Ciciarelli et al. Jul 1999 A
5935078 Feierbach Aug 1999 A
5941906 Barreras et al. Aug 1999 A
5944744 Paul et al. Aug 1999 A
5954757 Gray Sep 1999 A
5978713 Prutchi et al. Nov 1999 A
5991660 Goyal Nov 1999 A
5991661 Park et al. Nov 1999 A
5999848 Gord et al. Dec 1999 A
5999857 Weijand et al. Dec 1999 A
6016445 Baura Jan 2000 A
6026320 Carlson et al. Feb 2000 A
6029085 Olson et al. Feb 2000 A
6041250 dePinto Mar 2000 A
6044298 Salo et al. Mar 2000 A
6044300 Gray Mar 2000 A
6055454 Heemels Apr 2000 A
6073050 Griffith Jun 2000 A
6076016 Feierbach Jun 2000 A
6077236 Cunningham Jun 2000 A
6080187 Alt et al. Jun 2000 A
6083248 Thompson Jul 2000 A
6106551 Crossett et al. Aug 2000 A
6115636 Ryan Sep 2000 A
6128526 Stadler et al. Oct 2000 A
6141581 Colson et al. Oct 2000 A
6141588 Cox et al. Oct 2000 A
6141592 Pauly Oct 2000 A
6144879 Gray Nov 2000 A
6162195 Igo et al. Dec 2000 A
6164284 Schulman et al. Dec 2000 A
6167310 Grevious Dec 2000 A
6201993 Kruse et al. Mar 2001 B1
6208894 Schulman et al. Mar 2001 B1
6211799 Post et al. Apr 2001 B1
6221011 Bardy Apr 2001 B1
6240316 Richmond et al. May 2001 B1
6240317 Villaseca et al. May 2001 B1
6256534 Dahl Jul 2001 B1
6259947 Olson et al. Jul 2001 B1
6266558 Gozani et al. Jul 2001 B1
6266567 Ishikawa et al. Jul 2001 B1
6270457 Bardy Aug 2001 B1
6272377 Sweeney et al. Aug 2001 B1
6273856 Sun et al. Aug 2001 B1
6277072 Bardy Aug 2001 B1
6280380 Bardy Aug 2001 B1
6285907 Kramer et al. Sep 2001 B1
6292698 Duffin et al. Sep 2001 B1
6295473 Rosar Sep 2001 B1
6297943 Carson Oct 2001 B1
6298271 Weijand Oct 2001 B1
6307751 Bodony et al. Oct 2001 B1
6312378 Bardy Nov 2001 B1
6315721 Schulman et al. Nov 2001 B2
6336903 Bardy Jan 2002 B1
6345202 Richmond et al. Feb 2002 B2
6351667 Godie Feb 2002 B1
6351669 Hartley et al. Feb 2002 B1
6353759 Hartley et al. Mar 2002 B1
6358203 Bardy Mar 2002 B2
6361780 Ley et al. Mar 2002 B1
6368284 Bardy Apr 2002 B1
6371922 Baumann et al. Apr 2002 B1
6398728 Bardy Jun 2002 B1
6400982 Sweeney et al. Jun 2002 B2
6400990 Silvian Jun 2002 B1
6408208 Sun Jun 2002 B1
6409674 Brockway et al. Jun 2002 B1
6411848 Kramer et al. Jun 2002 B2
6424865 Ding Jul 2002 B1
6434429 Kraus et al. Aug 2002 B1
6438410 Hsu et al. Aug 2002 B2
6438417 Rockwell et al. Aug 2002 B1
6438421 Stahmann et al. Aug 2002 B1
6440066 Bardy Aug 2002 B1
6441747 Khair et al. Aug 2002 B1
6442426 Kroll Aug 2002 B1
6442432 Lee Aug 2002 B2
6443891 Grevious Sep 2002 B1
6445953 Bulkes et al. Sep 2002 B1
6453200 Koslar Sep 2002 B1
6456256 Amundson Sep 2002 B1
6459929 Hopper et al. Oct 2002 B1
6470215 Kraus et al. Oct 2002 B1
6471645 Warkentin et al. Oct 2002 B1
6480745 Nelson et al. Nov 2002 B2
6487443 Olson et al. Nov 2002 B2
6490487 Kraus et al. Dec 2002 B1
6498951 Larson et al. Dec 2002 B1
6507755 Gozani et al. Jan 2003 B1
6507759 Prutchi et al. Jan 2003 B1
6512940 Brabec et al. Jan 2003 B1
6522915 Ceballos et al. Feb 2003 B1
6526311 Begemann Feb 2003 B2
6539253 Thompson et al. Mar 2003 B2
6542775 Ding et al. Apr 2003 B2
6553258 Stahmann et al. Apr 2003 B2
6561975 Pool et al. May 2003 B1
6564807 Schulman et al. May 2003 B1
6574506 Kramer et al. Jun 2003 B2
6584351 Ekwall Jun 2003 B1
6584352 Combs et al. Jun 2003 B2
6597948 Rockwell et al. Jul 2003 B1
6597951 Kramer et al. Jul 2003 B2
6622046 Fraley et al. Sep 2003 B2
6628985 Sweeney et al. Sep 2003 B2
6647292 Bardy et al. Nov 2003 B1
6666844 Igo et al. Dec 2003 B1
6689117 Sweeney et al. Feb 2004 B2
6690959 Thompson Feb 2004 B2
6694189 Begemann Feb 2004 B2
6704602 Berg et al. Mar 2004 B2
6718212 Parry et al. Apr 2004 B2
6721597 Bardy et al. Apr 2004 B1
6738670 Almendinger et al. May 2004 B1
6746797 Benson et al. Jun 2004 B2
6749566 Russ Jun 2004 B2
6758810 Lebel et al. Jul 2004 B2
6763269 Cox Jul 2004 B2
6778860 Ostroff et al. Aug 2004 B2
6788971 Sloman et al. Sep 2004 B1
6788974 Bardy et al. Sep 2004 B2
6804558 Haller et al. Oct 2004 B2
6807442 Myklebust et al. Oct 2004 B1
6847844 Sun et al. Jan 2005 B2
6871095 Stahmann et al. Mar 2005 B2
6878112 Linberg et al. Apr 2005 B2
6885889 Chinchoy Apr 2005 B2
6892094 Ousdigian et al. May 2005 B2
6897788 Khair et al. May 2005 B2
6904315 Panken et al. Jun 2005 B2
6922592 Thompson et al. Jul 2005 B2
6931282 Esler Aug 2005 B2
6934585 Schloss et al. Aug 2005 B1
6957107 Rogers et al. Oct 2005 B2
6978176 Lattouf Dec 2005 B2
6985773 Von Arx et al. Jan 2006 B2
6990375 Kloss et al. Jan 2006 B2
7001366 Ballard Feb 2006 B2
7003350 Denker et al. Feb 2006 B2
7006864 Echt et al. Feb 2006 B2
7013178 Reinke et al. Mar 2006 B2
7027871 Bumes et al. Apr 2006 B2
7050849 Echt et al. May 2006 B2
7060031 Webb et al. Jun 2006 B2
7063693 Guenst Jun 2006 B2
7082336 Ransbury et al. Jul 2006 B2
7085606 Flach et al. Aug 2006 B2
7092758 Sun et al. Aug 2006 B2
7110824 Amundson et al. Sep 2006 B2
7120504 Osypka Oct 2006 B2
7130681 Gebhardt et al. Oct 2006 B2
7139613 Reinke et al. Nov 2006 B2
7142912 Wagner et al. Nov 2006 B2
7146225 Guenst et al. Dec 2006 B2
7146226 Lau et al. Dec 2006 B2
7149581 Goedeke Dec 2006 B2
7149588 Lau et al. Dec 2006 B2
7158839 Lau Jan 2007 B2
7162307 Patrias Jan 2007 B2
7164952 Lau et al. Jan 2007 B2
7177700 Cox Feb 2007 B1
7181505 Haller et al. Feb 2007 B2
7184830 Echt et al. Feb 2007 B2
7186214 Ness Mar 2007 B2
7191015 Lamson et al. Mar 2007 B2
7200437 Nabutovsky et al. Apr 2007 B1
7200439 Zdeblick et al. Apr 2007 B2
7206423 Feng et al. Apr 2007 B1
7209785 Kim et al. Apr 2007 B2
7209790 Thompson et al. Apr 2007 B2
7211884 Davis et al. May 2007 B1
7212871 Morgan May 2007 B1
7226440 Gelfand et al. Jun 2007 B2
7228183 Sun et al. Jun 2007 B2
7236821 Cates et al. Jun 2007 B2
7236829 Farazi et al. Jun 2007 B1
7254448 Almendinger et al. Aug 2007 B2
7260436 Kilgore et al. Aug 2007 B2
7270669 Sra Sep 2007 B1
7272448 Morgan et al. Sep 2007 B1
7277755 Falkenberg et al. Oct 2007 B1
7280872 Mosesov et al. Oct 2007 B1
7288096 Chin Oct 2007 B2
7289847 Gill et al. Oct 2007 B1
7289852 Helfinstine et al. Oct 2007 B2
7289853 Campbell et al. Oct 2007 B1
7289855 Nghiem et al. Oct 2007 B2
7302294 Kamath et al. Nov 2007 B2
7305266 Kroll Dec 2007 B1
7310556 Bulkes Dec 2007 B2
7319905 Morgan et al. Jan 2008 B1
7333853 Mazar et al. Feb 2008 B2
7336994 Hettrick et al. Feb 2008 B2
7347819 Lebel et al. Mar 2008 B2
7366572 Heruth et al. Apr 2008 B2
7373207 Lattouf May 2008 B2
7384403 Sherman Jun 2008 B2
7386342 Falkenberg et al. Jun 2008 B1
7392090 Sweeney et al. Jun 2008 B2
7406105 DelMain et al. Jul 2008 B2
7406349 Seeberger et al. Jul 2008 B2
7410497 Hastings et al. Aug 2008 B2
7425200 Brockway et al. Sep 2008 B2
7433739 Salys et al. Oct 2008 B1
7496409 Greenhut et al. Feb 2009 B2
7496410 Heil Feb 2009 B2
7502652 Gaunt et al. Mar 2009 B2
7512448 Malick et al. Mar 2009 B2
7515969 Tockman et al. Apr 2009 B2
7526342 Chin et al. Apr 2009 B2
7529589 Williams et al. May 2009 B2
7532933 Hastings et al. May 2009 B2
7536222 Bardy et al. May 2009 B2
7536224 Ritscher et al. May 2009 B2
7539541 Quiles et al. May 2009 B2
7544197 Kelsch et al. Jun 2009 B2
7558631 Cowan et al. Jul 2009 B2
7565195 Kroll et al. Jul 2009 B1
7584002 Burnes et al. Sep 2009 B2
7590455 Heruth et al. Sep 2009 B2
7606621 Brisken et al. Oct 2009 B2
7610088 Chinchoy Oct 2009 B2
7610092 Cowan et al. Oct 2009 B2
7610099 Almendinger et al. Oct 2009 B2
7610104 Kaplan et al. Oct 2009 B2
7616991 Mann et al. Nov 2009 B2
7617001 Penner et al. Nov 2009 B2
7617007 Williams et al. Nov 2009 B2
7630767 Poore et al. Dec 2009 B1
7634313 Kroll et al. Dec 2009 B1
7637867 Zdeblick Dec 2009 B2
7640060 Zdeblick Dec 2009 B2
7647109 Hastings et al. Jan 2010 B2
7650186 Hastings et al. Jan 2010 B2
7657311 Bardy et al. Feb 2010 B2
7668596 Von Arx et al. Feb 2010 B2
7682316 Anderson et al. Mar 2010 B2
7691047 Ferrari Apr 2010 B2
7702392 Echt et al. Apr 2010 B2
7713194 Zdeblick May 2010 B2
7713195 Zdeblick May 2010 B2
7729783 Michels et al. Jun 2010 B2
7734333 Ghanem et al. Jun 2010 B2
7734343 Ransbury et al. Jun 2010 B2
7738958 Zdeblick et al. Jun 2010 B2
7738964 Von Arx et al. Jun 2010 B2
7742812 Ghanem et al. Jun 2010 B2
7742816 Masoud et al. Jun 2010 B2
7742822 Masoud et al. Jun 2010 B2
7743151 Vallapureddy et al. Jun 2010 B2
7747335 Williams Jun 2010 B2
7751881 Cowan et al. Jul 2010 B2
7758521 Morris et al. Jul 2010 B2
7761150 Ghanem et al. Jul 2010 B2
7761164 Verhoef et al. Jul 2010 B2
7765001 Echt et al. Jul 2010 B2
7769452 Ghanem et al. Aug 2010 B2
7783362 Whitehurst et al. Aug 2010 B2
7792588 Harding Sep 2010 B2
7797059 Bornzin et al. Sep 2010 B1
7801596 Fischell et al. Sep 2010 B2
7809438 Echt et al. Oct 2010 B2
7840281 Kveen et al. Nov 2010 B2
7844331 Li et al. Nov 2010 B2
7844348 Swoyer et al. Nov 2010 B2
7846088 Ness Dec 2010 B2
7848815 Brisken et al. Dec 2010 B2
7848823 Drasler et al. Dec 2010 B2
7860455 Fukumoto et al. Dec 2010 B2
7871433 Lattouf Jan 2011 B2
7877136 Moffitt et al. Jan 2011 B1
7877142 Moaddeb et al. Jan 2011 B2
7881786 Jackson Feb 2011 B2
7881798 Miesel et al. Feb 2011 B2
7881810 Chitre et al. Feb 2011 B1
7890173 Brisken et al. Feb 2011 B2
7890181 Denzene et al. Feb 2011 B2
7890192 Kelsch et al. Feb 2011 B1
7894885 Bartal et al. Feb 2011 B2
7894894 Stadler et al. Feb 2011 B2
7894907 Cowan et al. Feb 2011 B2
7894910 Cowan et al. Feb 2011 B2
7894915 Chitre et al. Feb 2011 B1
7899537 Kroll et al. Mar 2011 B1
7899541 Cowan et al. Mar 2011 B2
7899542 Cowan et al. Mar 2011 B2
7899554 Williams et al. Mar 2011 B2
7901360 Yang et al. Mar 2011 B1
7904170 Harding Mar 2011 B2
7907993 Ghanem et al. Mar 2011 B2
7920928 Yang et al. Apr 2011 B1
7925343 Min et al. Apr 2011 B1
7930022 Zhang et al. Apr 2011 B2
7930040 Kelsch et al. Apr 2011 B1
7937135 Ghanem et al. May 2011 B2
7937148 Jacobson May 2011 B2
7937161 Hastings et al. May 2011 B2
7941214 Kleckner et al. May 2011 B2
7945333 Jacobson May 2011 B2
7946997 Hübinette May 2011 B2
7949404 Hill May 2011 B2
7949405 Feher May 2011 B2
7953486 Daum et al. May 2011 B2
7953493 Fowler et al. May 2011 B2
7962202 Bhunia Jun 2011 B2
7974702 Fain et al. Jul 2011 B1
7979136 Young et al. Jul 2011 B2
7983753 Severin Jul 2011 B2
7991467 Markowitz et al. Aug 2011 B2
7991471 Ghanem et al. Aug 2011 B2
7996087 Cowan et al. Aug 2011 B2
8000791 Sunagawa et al. Aug 2011 B2
8000807 Morris et al. Aug 2011 B2
8001975 DiSilvestro et al. Aug 2011 B2
8002700 Ferek-Petric et al. Aug 2011 B2
8010209 Jacobson Aug 2011 B2
8019419 Panescu et al. Sep 2011 B1
8019434 Quiles et al. Sep 2011 B2
8027727 Freeberg Sep 2011 B2
8027729 Sunagawa et al. Sep 2011 B2
8032219 Neumann et al. Oct 2011 B2
8036743 Savage et al. Oct 2011 B2
8046079 Bange et al. Oct 2011 B2
8046080 Von Arx et al. Oct 2011 B2
8050297 Delmain et al. Nov 2011 B2
8050759 Stegemann et al. Nov 2011 B2
8050774 Kveen et al. Nov 2011 B2
8055345 Li et al. Nov 2011 B2
8055350 Roberts Nov 2011 B2
8060212 Rios et al. Nov 2011 B1
8065018 Haubrich et al. Nov 2011 B2
8073542 Doerr Dec 2011 B2
8078278 Penner Dec 2011 B2
8078283 Cowan et al. Dec 2011 B2
8095123 Gray Jan 2012 B2
8102789 Rosar et al. Jan 2012 B2
8103359 Reddy Jan 2012 B2
8103361 Moser Jan 2012 B2
8112148 Giftakis et al. Feb 2012 B2
8114021 Robertson et al. Feb 2012 B2
8121680 Falkenberg et al. Feb 2012 B2
8123684 Zdeblick Feb 2012 B2
8126545 Flach et al. Feb 2012 B2
8131334 Lu et al. Mar 2012 B2
8140161 Willerton et al. Mar 2012 B2
8150521 Crowley et al. Apr 2012 B2
8160672 Kim et al. Apr 2012 B2
8160702 Mann et al. Apr 2012 B2
8160704 Freeberg Apr 2012 B2
8165694 Carbanaru et al. Apr 2012 B2
8175715 Cox May 2012 B1
8180451 Hickman et al. May 2012 B2
8185213 Kveen et al. May 2012 B2
8187161 Li et al. May 2012 B2
8195293 Limousin et al. Jun 2012 B2
8204595 Pianca et al. Jun 2012 B2
8204605 Hastings et al. Jun 2012 B2
8209014 Doerr Jun 2012 B2
8214043 Matos Jul 2012 B2
8224244 Kim et al. Jul 2012 B2
8229556 Li Jul 2012 B2
8233985 Bulkes et al. Jul 2012 B2
8265748 Liu et al. Sep 2012 B2
8265757 Mass et al. Sep 2012 B2
8262578 Bharmi et al. Oct 2012 B1
8280521 Haubrich et al. Oct 2012 B2
8285387 Utsi et al. Oct 2012 B2
8290598 Boon et al. Oct 2012 B2
8290600 Hastings et al. Oct 2012 B2
8295939 Jacobson Oct 2012 B2
8301254 Mosesov et al. Oct 2012 B2
8315701 Cowan et al. Nov 2012 B2
8315708 Berthelsdorf et al. Nov 2012 B2
8321021 Kisker et al. Nov 2012 B2
8321036 Brockway et al. Nov 2012 B2
8332036 Hastings et al. Dec 2012 B2
8335563 Stessman Dec 2012 B2
8335568 Heruth et al. Dec 2012 B2
8340750 Prakash et al. Dec 2012 B2
8340780 Hastings et al. Dec 2012 B2
8352025 Jacobson Jan 2013 B2
8352028 Wenger Jan 2013 B2
8352038 Mao et al. Jan 2013 B2
8359098 Lund et al. Jan 2013 B2
8364261 Stubbs et al. Jan 2013 B2
8364276 Willis Jan 2013 B2
8369959 Meskens Feb 2013 B2
8369962 Abrahamson Feb 2013 B2
8380320 Spital Feb 2013 B2
8386051 Rys Feb 2013 B2
8391981 Mosesov Mar 2013 B2
8391990 Smith et al. Mar 2013 B2
8406874 Liu et al. Mar 2013 B2
8406879 Shuros et al. Mar 2013 B2
8406886 Gaunt et al. Mar 2013 B2
8412352 Griswold et al. Apr 2013 B2
8417340 Goossen Apr 2013 B2
8417341 Freeberg Apr 2013 B2
8423149 Hennig Apr 2013 B2
8428722 Verhoef et al. Apr 2013 B2
8433402 Ruben et al. Apr 2013 B2
8433409 Johnson et al. Apr 2013 B2
8433420 Bange et al. Apr 2013 B2
8447412 Dal Molin et al. May 2013 B2
8452413 Young et al. May 2013 B2
8457740 Osche Jun 2013 B2
8457742 Jacobson Jun 2013 B2
8457744 Janzig et al. Jun 2013 B2
8457761 Wariar Jun 2013 B2
8478407 Demmer et al. Jul 2013 B2
8478408 Hastings et al. Jul 2013 B2
8478431 Griswold et al. Jul 2013 B2
8494632 Sun et al. Jul 2013 B2
8504156 Bonner et al. Aug 2013 B2
8509910 Sowder et al. Aug 2013 B2
8515559 Roberts et al. Aug 2013 B2
8525340 Eckhardt et al. Sep 2013 B2
8527068 Ostroff Sep 2013 B2
8532790 Griswold Sep 2013 B2
8538526 Stahmann et al. Sep 2013 B2
8541131 Lund et al. Sep 2013 B2
8543205 Ostroff Sep 2013 B2
8547248 Zdeblick et al. Oct 2013 B2
8548605 Ollivier Oct 2013 B2
8554333 Wu et al. Oct 2013 B2
8565882 Matos Oct 2013 B2
8565897 Regnier et al. Oct 2013 B2
8571678 Wang Oct 2013 B2
8577327 Makdissi et al. Nov 2013 B2
8588926 Moore et al. Nov 2013 B2
8612002 Faltys et al. Dec 2013 B2
8615310 Khairkhahan et al. Dec 2013 B2
8626280 Allavatam et al. Jan 2014 B2
8626294 Sheldon et al. Jan 2014 B2
8634908 Cowan Jan 2014 B2
8634912 Bornzin et al. Jan 2014 B2
8634919 Hou et al. Jan 2014 B1
8639335 Peichel et al. Jan 2014 B2
8644934 Hastings et al. Feb 2014 B2
8649859 Smith et al. Feb 2014 B2
8670842 Bornzin et al. Mar 2014 B1
8676319 Knoll Mar 2014 B2
8676335 Katoozi et al. Mar 2014 B2
8700173 Edlund Apr 2014 B2
8700181 Bornzin et al. Apr 2014 B2
8705599 dal Molin et al. Apr 2014 B2
8718766 Wahlberg May 2014 B2
8718773 Willis et al. May 2014 B2
8725260 Shuros et al. May 2014 B2
8738133 Shuros et al. May 2014 B2
8738147 Hastings et al. May 2014 B2
8744555 Allavatam et al. Jun 2014 B2
8744572 Greenhut et al. Jun 2014 B1
8747314 Stahmann et al. Jun 2014 B2
8755884 Demmer et al. Jun 2014 B2
8758365 Bonner et al. Jun 2014 B2
8768483 Schmitt et al. Jul 2014 B2
8774572 Hamamoto Jul 2014 B2
8781605 Bomzin et al. Jul 2014 B2
8788035 Jacobson Jul 2014 B2
8788053 Jacobson Jul 2014 B2
8798740 Samade et al. Aug 2014 B2
8798745 Jacobson Aug 2014 B2
8798762 Fain et al. Aug 2014 B2
8798770 Reddy Aug 2014 B2
8805505 Roberts Aug 2014 B1
8805528 Corndorf Aug 2014 B2
8812109 Blomqvist et al. Aug 2014 B2
8818504 Bodner et al. Aug 2014 B2
8827913 Havel et al. Sep 2014 B2
8831747 Min et al. Sep 2014 B1
8855789 Jacobson Oct 2014 B2
8868186 Kroll Oct 2014 B2
8886339 Faltys et al. Nov 2014 B2
8903473 Rogers et al. Dec 2014 B2
8903500 Smith et al. Dec 2014 B2
8903513 Ollivier Dec 2014 B2
8909336 Navarro-Paredes et al. Dec 2014 B2
8914131 Bornzin et al. Dec 2014 B2
8923795 Makdissi et al. Dec 2014 B2
8923963 Bonner et al. Dec 2014 B2
8938300 Rosero Jan 2015 B2
8942806 Sheldon et al. Jan 2015 B2
8958892 Khairkhahan et al. Feb 2015 B2
8977358 Ewert et al. Mar 2015 B2
8989873 Locsin Mar 2015 B2
8996109 Karst et al. Mar 2015 B2
9002467 Smith et al. Apr 2015 B2
9008776 Cowan et al. Apr 2015 B2
9008777 Dianaty et al. Apr 2015 B2
9014818 Deterre et al. Apr 2015 B2
9017341 Bornzin et al. Apr 2015 B2
9020611 Khairkhahan et al. Apr 2015 B2
9037262 Regnier et al. May 2015 B2
9042984 Demmer et al. May 2015 B2
9072911 Hastings et al. Jul 2015 B2
9072913 Jacobson Jul 2015 B2
9155882 Grubac et al. Oct 2015 B2
9168372 Fain Oct 2015 B2
9168380 Greenhut et al. Oct 2015 B1
9168383 Jacobson et al. Oct 2015 B2
9180285 Moore et al. Nov 2015 B2
9192774 Jacobson Nov 2015 B2
9205225 Khairkhahan et al. Dec 2015 B2
9216285 Boling et al. Dec 2015 B1
9216293 Berthiaume et al. Dec 2015 B2
9216298 Jacobson Dec 2015 B2
9227077 Jacobson Jan 2016 B2
9238145 Wenzel et al. Jan 2016 B2
9242102 Khairkhahan et al. Jan 2016 B2
9242113 Smith et al. Jan 2016 B2
9248300 Rys et al. Feb 2016 B2
9265436 Min et al. Feb 2016 B2
9265962 Dianaty et al. Feb 2016 B2
9272155 Ostroff Mar 2016 B2
9278218 Karst et al. Mar 2016 B2
9278229 Reinke et al. Mar 2016 B1
9283381 Grubac et al. Mar 2016 B2
9283382 Berthiaume et al. Mar 2016 B2
9289612 Sambelashvili et al. Mar 2016 B1
9302115 Molin et al. Apr 2016 B2
9333364 Echt et al. May 2016 B2
9358387 Suwito et al. Jun 2016 B2
9358400 Jacobson Jun 2016 B2
9364675 Deterre et al. Jun 2016 B2
9370663 Moulder Jun 2016 B2
9375580 Bonner et al. Jun 2016 B2
9375581 Baru et al. Jun 2016 B2
9381365 Kibler et al. Jul 2016 B2
9393424 Demmer et al. Jul 2016 B2
9393436 Doerr Jul 2016 B2
9399139 Demmer et al. Jul 2016 B2
9399140 Cho et al. Jul 2016 B2
9409033 Jacobson Aug 2016 B2
9427594 Bornzin et al. Aug 2016 B1
9433368 Stahmann et al. Sep 2016 B2
9433780 Régnier et al. Sep 2016 B2
9457193 Klimovitch et al. Oct 2016 B2
9492668 Sheldon et al. Nov 2016 B2
9492669 Demmer et al. Nov 2016 B2
9492674 Schmidt et al. Nov 2016 B2
9492677 Greenhut et al. Nov 2016 B2
9511233 Sambelashvili Dec 2016 B2
9511236 Varady et al. Dec 2016 B2
9511237 Deterre et al. Dec 2016 B2
9522276 Shen et al. Dec 2016 B2
9522280 Fishier et al. Dec 2016 B2
9526522 Wood et al. Dec 2016 B2
9526891 Eggen et al. Dec 2016 B2
9526909 Stahmann et al. Dec 2016 B2
9533163 Klimovitch et al. Jan 2017 B2
9561382 Persson et al. Feb 2017 B2
9566012 Greenhut et al. Feb 2017 B2
9636511 Carney et al. May 2017 B2
9669223 Auricchio et al. Jun 2017 B2
9687654 Sheldon et al. Jun 2017 B2
9687655 Pertijs et al. Jun 2017 B2
9687659 Von Arx et al. Jun 2017 B2
9694186 Carney et al. Jul 2017 B2
20020032470 Linberg Mar 2002 A1
20020035376 Bardy et al. Mar 2002 A1
20020035377 Bardy et al. Mar 2002 A1
20020035378 Bardy et al. Mar 2002 A1
20020035380 Rissmann et al. Mar 2002 A1
20020035381 Bardy et al. Mar 2002 A1
20020042629 Bardy et al. Apr 2002 A1
20020042630 Bardy et al. Apr 2002 A1
20020042634 Bardy et al. Apr 2002 A1
20020049475 Bardy et al. Apr 2002 A1
20020052636 Bardy et al. May 2002 A1
20020068958 Bardy et al. Jun 2002 A1
20020072773 Bardy et al. Jun 2002 A1
20020082665 Haller et al. Jun 2002 A1
20020091414 Bardy et al. Jul 2002 A1
20020095196 Linberg Jul 2002 A1
20020099423 Berg et al. Jul 2002 A1
20020103510 Bardy et al. Aug 2002 A1
20020107545 Rissmann et al. Aug 2002 A1
20020107546 Ostroff et al. Aug 2002 A1
20020107547 Erlinger et al. Aug 2002 A1
20020107548 Bardy et al. Aug 2002 A1
20020107549 Bardy et al. Aug 2002 A1
20020107559 Sanders et al. Aug 2002 A1
20020120299 Ostroff et al. Aug 2002 A1
20020173830 Starkweather et al. Nov 2002 A1
20020193846 Pool et al. Dec 2002 A1
20030009203 Lebel et al. Jan 2003 A1
20030028082 Thompson Feb 2003 A1
20030040779 Engmark et al. Feb 2003 A1
20030041866 Linberg et al. Mar 2003 A1
20030045805 Sheldon et al. Mar 2003 A1
20030088278 Bardy et al. May 2003 A1
20030097153 Bardy et al. May 2003 A1
20030105497 Zhu et al. Jun 2003 A1
20030114908 Flach Jun 2003 A1
20030144701 Mehra et al. Jul 2003 A1
20030187460 Chin et al. Oct 2003 A1
20030187461 Chin Oct 2003 A1
20040024435 Leckrone et al. Feb 2004 A1
20040068302 Rodgers et al. Apr 2004 A1
20040087938 Leckrone et al. May 2004 A1
20040088035 Guenst et al. May 2004 A1
20040102830 Williams May 2004 A1
20040127959 Amundson et al. Jul 2004 A1
20040133242 Chapman et al. Jul 2004 A1
20040147969 Mann et al. Jul 2004 A1
20040147973 Hauser Jul 2004 A1
20040167558 Igo et al. Aug 2004 A1
20040167587 Thompson Aug 2004 A1
20040172071 Bardy et al. Sep 2004 A1
20040172077 Chinchoy Sep 2004 A1
20040172104 Berg et al. Sep 2004 A1
20040176817 Wahlstrand et al. Sep 2004 A1
20040176818 Wahlstrand et al. Sep 2004 A1
20040176830 Fang Sep 2004 A1
20040186529 Bardy et al. Sep 2004 A1
20040204673 Flaherty Oct 2004 A1
20040210292 Bardy et al. Oct 2004 A1
20040210293 Bardy et al. Oct 2004 A1
20040210294 Bardy et al. Oct 2004 A1
20040215308 Bardy et al. Oct 2004 A1
20040220624 Ritscher et al. Nov 2004 A1
20040220626 Wagner Nov 2004 A1
20040220639 Mulligan et al. Nov 2004 A1
20040249431 Ransbury et al. Dec 2004 A1
20040260348 Bakken et al. Dec 2004 A1
20040267303 Guenst Dec 2004 A1
20050061320 Lee et al. Mar 2005 A1
20050070962 Echt et al. Mar 2005 A1
20050102003 Grabek et al. May 2005 A1
20050149138 Min et al. Jul 2005 A1
20050165466 Morris et al. Jul 2005 A1
20050182465 Ness Aug 2005 A1
20050203410 Jenkins Sep 2005 A1
20050283208 Von Arx et al. Dec 2005 A1
20050288743 Ahn et al. Dec 2005 A1
20060042830 Maghribi et al. Mar 2006 A1
20060052829 Sun et al. Mar 2006 A1
20060052830 Spinelli et al. Mar 2006 A1
20060064135 Brockway Mar 2006 A1
20060064149 Belacazar et al. Mar 2006 A1
20060085039 Hastings et al. Apr 2006 A1
20060085041 Hastings et al. Apr 2006 A1
20060085042 Hastings et al. Apr 2006 A1
20060095078 Tronnes May 2006 A1
20060106442 Richardson et al. May 2006 A1
20060116746 Chin Jun 2006 A1
20060135999 Bodner et al. Jun 2006 A1
20060136004 Cowan et al. Jun 2006 A1
20060161061 Echt et al. Jul 2006 A1
20060200002 Guenst Sep 2006 A1
20060206151 Lu Sep 2006 A1
20060206170 Denker Sep 2006 A1
20060212079 Routh et al. Sep 2006 A1
20060241701 Markowitz et al. Oct 2006 A1
20060241705 Neumann et al. Oct 2006 A1
20060247672 Vidlund et al. Nov 2006 A1
20060259088 Pastore et al. Nov 2006 A1
20060265018 Smith et al. Nov 2006 A1
20070004979 Wojciechowicz et al. Jan 2007 A1
20070016098 Kim et al. Jan 2007 A1
20070027508 Cowan Feb 2007 A1
20070078490 Cowan et al. Apr 2007 A1
20070088394 Jacobson Apr 2007 A1
20070088396 Jacobson Apr 2007 A1
20070088397 Jacobson Apr 2007 A1
20070088398 Jacobson Apr 2007 A1
20070088405 Jacobson Apr 2007 A1
20070135882 Drasler et al. Jun 2007 A1
20070135883 Drasler et al. Jun 2007 A1
20070150019 Youker et al. Jun 2007 A1
20070150037 Hastings et al. Jun 2007 A1
20070150038 Hastings et al. Jun 2007 A1
20070156190 Cinbis Jul 2007 A1
20070219525 Gelfand et al. Sep 2007 A1
20070219590 Hastings et al. Sep 2007 A1
20070225545 Ferrari Sep 2007 A1
20070233206 Frikart et al. Oct 2007 A1
20070239244 Morgan et al. Oct 2007 A1
20070255376 Michels et al. Nov 2007 A1
20070276444 Gelbart et al. Nov 2007 A1
20070293900 Sheldon et al. Dec 2007 A1
20070293904 Gelbart et al. Dec 2007 A1
20080004663 Jorgenson Jan 2008 A1
20080021505 Hastings et al. Jan 2008 A1
20080021519 De Geest et al. Jan 2008 A1
20080021532 Kveen et al. Jan 2008 A1
20080065183 Whitehurst et al. Mar 2008 A1
20080065185 Worley Mar 2008 A1
20080071318 Brooke et al. Mar 2008 A1
20080109054 Hastings et al. May 2008 A1
20080119911 Rosero May 2008 A1
20080130670 Kim et al. Jun 2008 A1
20080154139 Shuros et al. Jun 2008 A1
20080154322 Jackson et al. Jun 2008 A1
20080228234 Stancer Sep 2008 A1
20080234771 Chinchoy et al. Sep 2008 A1
20080243217 Wildon Oct 2008 A1
20080269814 Rosero Oct 2008 A1
20080269825 Chinchoy et al. Oct 2008 A1
20080275518 Ghanem et al. Nov 2008 A1
20080275519 Ghanem et al. Nov 2008 A1
20080288039 Reddy Nov 2008 A1
20080294208 Willis et al. Nov 2008 A1
20080294210 Rosero Nov 2008 A1
20080306359 Zdeblick et al. Dec 2008 A1
20090018599 Hastings et al. Jan 2009 A1
20090024180 Kisker et al. Jan 2009 A1
20090036941 Corbucci Feb 2009 A1
20090048646 Katoozi et al. Feb 2009 A1
20090062895 Stahmann et al. Mar 2009 A1
20090082827 Kveen et al. Mar 2009 A1
20090082828 Ostroff Mar 2009 A1
20090088813 Brockway et al. Apr 2009 A1
20090131907 Chin et al. May 2009 A1
20090135886 Robertson et al. May 2009 A1
20090143835 Pastore et al. Jun 2009 A1
20090171408 Solem Jul 2009 A1
20090171414 Kelly et al. Jul 2009 A1
20090204163 Shuros et al. Aug 2009 A1
20090204170 Hastings et al. Aug 2009 A1
20090210024 M Aug 2009 A1
20090216292 Pless et al. Aug 2009 A1
20090234407 Hastings et al. Sep 2009 A1
20090234411 Sambelashvili et al. Sep 2009 A1
20090266573 Engmark et al. Oct 2009 A1
20090275998 Burnes et al. Nov 2009 A1
20090275999 Burnes et al. Nov 2009 A1
20090299447 Jensen et al. Dec 2009 A1
20100013668 Kantervik Jan 2010 A1
20100016911 Willis et al. Jan 2010 A1
20100023085 Wu et al. Jan 2010 A1
20100030061 Canfield et al. Feb 2010 A1
20100030327 Chatel Feb 2010 A1
20100042108 Hibino Feb 2010 A1
20100056871 Govari et al. Mar 2010 A1
20100063375 Kassab et al. Mar 2010 A1
20100063562 Cowan et al. Mar 2010 A1
20100094367 Sen Apr 2010 A1
20100114209 Krause et al. May 2010 A1
20100114214 Morelli et al. May 2010 A1
20100125281 Jacobson et al. May 2010 A1
20100168761 Kassab et al. Jul 2010 A1
20100168819 Freeberg Jul 2010 A1
20100198288 Ostroff Aug 2010 A1
20100198304 Wang Aug 2010 A1
20100217367 Belson Aug 2010 A1
20100228308 Cowan et al. Sep 2010 A1
20100234906 Koh Sep 2010 A1
20100234924 Willis Sep 2010 A1
20100241185 Mahapatra et al. Sep 2010 A1
20100249729 Morris et al. Sep 2010 A1
20100286744 Echt et al. Nov 2010 A1
20100312309 Harding Dec 2010 A1
20110022113 Zdeblick et al. Jan 2011 A1
20110071586 Jacobson Mar 2011 A1
20110077708 Ostroff Mar 2011 A1
20110112600 Cowan et al. May 2011 A1
20110118588 Komblau et al. May 2011 A1
20110118810 Cowan et al. May 2011 A1
20110137187 Yang et al. Jun 2011 A1
20110144720 Cowan et al. Jun 2011 A1
20110152970 Jollota et al. Jun 2011 A1
20110160558 Rassatt et al. Jun 2011 A1
20110160565 Stubbs et al. Jun 2011 A1
20110160801 Markowitz et al. Jun 2011 A1
20110160806 Lyden et al. Jun 2011 A1
20110166620 Cowan et al. Jul 2011 A1
20110166621 Cowan et al. Jul 2011 A1
20110184491 Kivi Jul 2011 A1
20110190835 Brockway et al. Aug 2011 A1
20110208260 Jacobson Aug 2011 A1
20110218587 Jacobson Sep 2011 A1
20110230734 Fain et al. Sep 2011 A1
20110237967 Moore et al. Sep 2011 A1
20110245890 Brisben et al. Oct 2011 A1
20110251660 Griswold Oct 2011 A1
20110251662 Griswold et al. Oct 2011 A1
20110270099 Ruben et al. Nov 2011 A1
20110270339 Murray, III et al. Nov 2011 A1
20110270340 Pellegrini et al. Nov 2011 A1
20110276102 Cohen Nov 2011 A1
20110276111 Carbunaru et al. Nov 2011 A1
20110282423 Jacobson Nov 2011 A1
20120004527 Thompson et al. Jan 2012 A1
20120029323 Zhao Feb 2012 A1
20120041508 Rousso et al. Feb 2012 A1
20120059433 Cowan et al. Mar 2012 A1
20120059436 Fontaine et al. Mar 2012 A1
20120065500 Rogers et al. Mar 2012 A1
20120078322 Dal Molin et al. Mar 2012 A1
20120089198 Ostroff Apr 2012 A1
20120093245 Makdissi et al. Apr 2012 A1
20120095521 Hintz Apr 2012 A1
20120095539 Khairkhahan et al. Apr 2012 A1
20120101540 O'Brien et al. Apr 2012 A1
20120101553 Reddy Apr 2012 A1
20120109148 Bonner et al. May 2012 A1
20120109149 Bonner et al. May 2012 A1
20120109236 Jacobson et al. May 2012 A1
20120109259 Bond et al. May 2012 A1
20120116489 Khairkhahan et al. May 2012 A1
20120150251 Giftakis et al. Jun 2012 A1
20120158111 Khairkhahan et al. Jun 2012 A1
20120165827 Khairkhahan et al. Jun 2012 A1
20120172690 Anderson et al. Jul 2012 A1
20120172891 Lee Jul 2012 A1
20120172892 Grubac et al. Jul 2012 A1
20120172942 Berg Jul 2012 A1
20120197350 Roberts et al. Aug 2012 A1
20120197373 Khairkhahan et al. Aug 2012 A1
20120215285 Tahmasian et al. Aug 2012 A1
20120232565 Kveen et al. Sep 2012 A1
20120277600 Greenhut Nov 2012 A1
20120277606 Ellingson et al. Nov 2012 A1
20120283795 Stancer et al. Nov 2012 A1
20120283807 Deterre et al. Nov 2012 A1
20120290025 Keimel Nov 2012 A1
20120296381 Mates Nov 2012 A1
20120303082 Dong et al. Nov 2012 A1
20120316613 Keefe et al. Dec 2012 A1
20130012151 Hankins Jan 2013 A1
20130023975 Locsin Jan 2013 A1
20130035748 Bonner et al. Feb 2013 A1
20130041422 Jacobson Feb 2013 A1
20130053908 Smith et al. Feb 2013 A1
20130053915 Holmstrom et al. Feb 2013 A1
20130053921 Bonner et al. Feb 2013 A1
20130060298 Splett et al. Mar 2013 A1
20130066169 Rys et al. Mar 2013 A1
20130072770 Rao et al. Mar 2013 A1
20130079798 Tran et al. Mar 2013 A1
20130079861 Reinert et al. Mar 2013 A1
20130085350 Schugt et al. Apr 2013 A1
20130085403 Gunderson et al. Apr 2013 A1
20130085550 Polefko et al. Apr 2013 A1
20130096649 Martin et al. Apr 2013 A1
20130103047 Steingisser et al. Apr 2013 A1
20130103109 Jacobson Apr 2013 A1
20130110008 Bourget et al. May 2013 A1
20130110127 Bornzin et al. May 2013 A1
20130110192 Tran et al. May 2013 A1
20130110219 Bornzin et al. May 2013 A1
20130116529 Min et al. May 2013 A1
20130116738 Samade et al. May 2013 A1
20130116740 Bornzin et al. May 2013 A1
20130116741 Bornzin et al. May 2013 A1
20130123872 Bornzin et al. May 2013 A1
20130123875 Varady et al. May 2013 A1
20130131591 Berthiaume et al. May 2013 A1
20130131693 Berthiaume et al. May 2013 A1
20130138006 Bornzin et al. May 2013 A1
20130150695 Biela et al. Jun 2013 A1
20130150911 Perschbacher et al. Jun 2013 A1
20130150912 Perschbacher et al. Jun 2013 A1
20130184776 Shuros et al. Jul 2013 A1
20130196703 Masoud et al. Aug 2013 A1
20130197609 Moore et al. Aug 2013 A1
20130231710 Jacobson Sep 2013 A1
20130238072 Deterre et al. Sep 2013 A1
20130238073 Makdissi et al. Sep 2013 A1
20130253342 Griswold et al. Sep 2013 A1
20130253343 Waldhauser et al. Sep 2013 A1
20130253344 Griswold et al. Sep 2013 A1
20130253345 Griswold et al. Sep 2013 A1
20130253346 Griswold et al. Sep 2013 A1
20130253347 Griswold et al. Sep 2013 A1
20130261497 Pertijs et al. Oct 2013 A1
20130265144 Banna et al. Oct 2013 A1
20130268042 Hastings et al. Oct 2013 A1
20130274828 Willis Oct 2013 A1
20130274847 Ostroff Oct 2013 A1
20130282070 Cowan et al. Oct 2013 A1
20130282073 Cowan et al. Oct 2013 A1
20130296727 Sullivan et al. Nov 2013 A1
20130303872 Taff et al. Nov 2013 A1
20130324825 Ostroff et al. Dec 2013 A1
20130325081 Karst et al. Dec 2013 A1
20130345770 Dianaty et al. Dec 2013 A1
20140012344 Hastings et al. Jan 2014 A1
20140018876 Ostroff Jan 2014 A1
20140018877 Demmer et al. Jan 2014 A1
20140031836 Ollivier Jan 2014 A1
20140039570 Carroll et al. Feb 2014 A1
20140039591 Drasler et al. Feb 2014 A1
20140043146 Makdissi et al. Feb 2014 A1
20140046395 Regnier et al. Feb 2014 A1
20140046420 Moore et al. Feb 2014 A1
20140058240 Mothilal et al. Feb 2014 A1
20140058494 Ostroff et al. Feb 2014 A1
20140074114 Khairkhahan Mar 2014 A1
20140074186 Faltys et al. Mar 2014 A1
20140094891 Pare et al. Apr 2014 A1
20140100627 Min Apr 2014 A1
20140107723 Hou et al. Apr 2014 A1
20140121719 Bonner et al. May 2014 A1
20140121720 Bonner et al. May 2014 A1
20140121722 Sheldon et al. May 2014 A1
20140128935 Kumar et al. May 2014 A1
20140135865 Hastings et al. May 2014 A1
20140142648 Smith et al. May 2014 A1
20140148675 Nordstrom et al. May 2014 A1
20140148815 Wenzel et al. May 2014 A1
20140155950 Hastings et al. Jun 2014 A1
20140169162 Romano et al. Jun 2014 A1
20140172060 Bornzin et al. Jun 2014 A1
20140180306 Grubac et al. Jun 2014 A1
20140180366 Edlund Jun 2014 A1
20140207149 Hastings et al. Jul 2014 A1
20140207210 Willis et al. Jul 2014 A1
20140214104 Greenhut et al. Jul 2014 A1
20140222098 Baru et al. Aug 2014 A1
20140222109 Moulder Aug 2014 A1
20140228913 Molin et al. Aug 2014 A1
20140236172 Hastings et al. Aug 2014 A1
20140243848 Auricchio et al. Aug 2014 A1
20140255298 Cole et al. Sep 2014 A1
20140257324 Fain Sep 2014 A1
20140257422 Herken Sep 2014 A1
20140257444 Cole et al. Sep 2014 A1
20140276929 Foster et al. Sep 2014 A1
20140303704 Suwito et al. Oct 2014 A1
20140309706 Jacobson Oct 2014 A1
20140379041 Foster Dec 2014 A1
20150025612 Haasl et al. Jan 2015 A1
20150039041 Smith et al. Feb 2015 A1
20150051609 Schmidt et al. Feb 2015 A1
20150051610 Schmidt et al. Feb 2015 A1
20150051611 Schmidt et al. Feb 2015 A1
20150051612 Schmidt et al. Feb 2015 A1
20150051613 Schmidt et al. Feb 2015 A1
20150051614 Schmidt et al. Feb 2015 A1
20150051615 Schmidt et al. Feb 2015 A1
20150051616 Haasl et al. Feb 2015 A1
20150051682 Schmidt et al. Feb 2015 A1
20150057520 Foster et al. Feb 2015 A1
20150057558 Stahmann et al. Feb 2015 A1
20150057721 Stahmann et al. Feb 2015 A1
20150088155 Stahmann et al. Mar 2015 A1
20150097734 Zhao Apr 2015 A1
20150100108 Vansickle et al. Apr 2015 A1
20150105836 Bonner et al. Apr 2015 A1
20150127068 Simon May 2015 A1
20150157861 Aghassian Jun 2015 A1
20150173655 Demmer et al. Jun 2015 A1
20150190638 Smith et al. Jul 2015 A1
20150196756 Stahmann et al. Jul 2015 A1
20150196757 Stahmann et al. Jul 2015 A1
20150196758 Stahmann et al. Jul 2015 A1
20150196769 Stahmann et al. Jul 2015 A1
20150217119 Nikolski et al. Aug 2015 A1
20150221898 Chi et al. Aug 2015 A1
20150224315 Stahmann Aug 2015 A1
20150224320 Stahmann Aug 2015 A1
20150231398 Marnfeldt Aug 2015 A1
20150258345 Smith et al. Sep 2015 A1
20150290468 Zhang Oct 2015 A1
20150297905 Greenhut et al. Oct 2015 A1
20150297907 Zhang Oct 2015 A1
20150305637 Greenhut et al. Oct 2015 A1
20150305638 Zhang Oct 2015 A1
20150305639 Greenhut et al. Oct 2015 A1
20150305640 Reinke et al. Oct 2015 A1
20150305641 Stadler et al. Oct 2015 A1
20150305642 Reinke et al. Oct 2015 A1
20150306374 Seifert et al. Oct 2015 A1
20150306375 Marshall et al. Oct 2015 A1
20150306406 Crutchfield et al. Oct 2015 A1
20150306407 Crutchfield et al. Oct 2015 A1
20150306408 Greenhut et al. Oct 2015 A1
20150321016 O'Brien et al. Nov 2015 A1
20150328459 Chin et al. Nov 2015 A1
20160015322 Anderson et al. Jan 2016 A1
20160023000 Cho et al. Jan 2016 A1
20160030757 Jacobson Feb 2016 A1
20160033177 Barot et al. Feb 2016 A1
20160121127 Klimovitch et al. May 2016 A1
20160121128 Fishler et al. May 2016 A1
20160121129 Persson et al. May 2016 A1
20160213919 Suwito et al. Jul 2016 A1
20160213937 Reinke et al. Jul 2016 A1
20160213939 Carney et al. Jul 2016 A1
20160228026 Jackson Aug 2016 A1
20160317825 Jacobson Nov 2016 A1
20160367823 Cowan et al. Dec 2016 A1
20170014629 Ghosh et al. Jan 2017 A1
20170035315 Jackson Feb 2017 A1
20170043173 Sharma et al. Feb 2017 A1
20170043174 Greenhut et al. Feb 2017 A1
20170189681 Anderson Jul 2017 A1
20180228397 Dumanli Oktar Aug 2018 A1
Foreign Referenced Citations (45)
Number Date Country
2008279789 Oct 2011 AU
2008329620 May 2014 AU
2014203793 Jul 2014 AU
1003904 Jan 1977 CA
202933393 May 2013 CN
0362611 Apr 1990 EP
603823 Sep 1992 EP
1702648 Sep 2006 EP
1904166 Jun 2011 EP
2433675 Jan 2013 EP
2441491 Jan 2013 EP
2452721 Nov 2013 EP
1948296 Jan 2014 EP
2662113 Jan 2014 EP
2471452 Dec 2014 EP
2760541 May 2016 EP
2833966 May 2016 EP
2000051373 Feb 2000 JP
2002502640 Jan 2002 JP
2004512105 Apr 2004 JP
2005508208 Mar 2005 JP
2005245215 Sep 2005 JP
2008540040 Nov 2008 JP
6199867 Feb 2013 JP
09500202 Jan 1995 WO
9636134 Nov 1996 WO
9724981 Jul 1997 WO
9826840 Jun 1998 WO
9939767 Aug 1999 WO
0234330 Jan 2003 WO
02098282 May 2003 WO
2005000206 Apr 2005 WO
2005042089 May 2005 WO
2006045075 Apr 2006 WO
2006065394 Jun 2006 WO
2006086435 Aug 2006 WO
2006113659 Oct 2006 WO
2006124833 May 2007 WO
2007075974 Jul 2007 WO
2009006531 Jan 2009 WO
2012054102 Apr 2012 WO
2013080038 Jun 2013 WO
2013098644 Aug 2013 WO
2013184787 Dec 2013 WO
2014120769 Aug 2014 WO
Non-Patent Literature Citations (8)
Entry
US 8,886,318 B2, 11/2014, Jacobson et al. (withdrawn)
Hachisuka et al., “Development and Performance Analysis of an Intra-Body Communication Device,” The 12th International Conference on Solid State Sensors, Actuators and Microsystems, vol. 4A1.3, pp. 1722-1725, 2003.
Seyedi et al., “A Survey on Intrabody Communications for Body Area Network Application,” IEEE Transactions on Biomedical Engineering,vol. 60(8): 2067-2079, 2013.
Wegmüller, “Intra-Body Communication for Biomedical Sensor Networks,” Diss. ETH, No. 17323, 1-173, 2007.
Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority, or the Declaration, Jan. 29, 2016, 15 pages.
Spickler et al., “Totally Self-Contained Intracardiac Pacemaker,” Journal of Electrocardiology, vol. 3(384): 324-331, 1970.
“Instructions for Use System 1, Leadless Cardiac Pacemaker (LCP) and Delivery Catheter,” Nanostim Leadless Pacemakers, pp. 1-28, 2013.
International Search Report and Written Opinion for Application No. PCT/US20171025384, 24 pages, dated Jun. 28, 2017.
Related Publications (1)
Number Date Country
20170281955 A1 Oct 2017 US
Provisional Applications (1)
Number Date Country
62316158 Mar 2016 US